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1 INTRODUCTION
1.1 Heart failure
According to the World Health Organization(WHO), cardiovascular diseases(CVDs) are the number 
one cause of death globally1. About 17.3 million people died from CVDs in 2008, representing 30% 
of all global deaths1. The number is expected to reach 23.3 million by the year 2030 and is 
projected to remain the single leading cause of death2. In industrial countries, CVDs account for 
45% of all deaths caused by non communicable diseases3. They are mainly caused by disorders of 
the heart and blood vessels and include coronary heart disease, cerebrovascular disease, 
hypertension, peripheral artery disease, rheumatic heart disease, congenital heart disease and heart 
failure.
Heart failure can be described as a deficiency in the function of the heart, preventing its ability to 
fulfill systemic demands leading to premature fatigue, dyspnoea and/or oedema4. It  can be induced 
by a number of stimuli, including hypertension, myocardial infarction, coronary artery  disease, 
valvular insufficiency and stenosis, myocarditis, congenital malformations, familial hypertrophic 
and dilated cardiomyopathies and diabetic cardiomyopathy5,6. End stage heart failure is 
characterized by the following (Fig 1): (1) a genetic reprogramming of the heart akin to the 
expression profile of a fetal heart  accompanied by differing degrees of cardiomyocyte hypertrophy; 
(2) necrotic or programmed cell death and excess extracellular matrix formation; (3) a reduction of 
capillarization and presence of regional ischemia, systemic and myocardial (neuro)humoral 
stimulation, (supra)ventricular dysrrhythmias and hemodynamic dysfunction at the systolic and/or 
diastolic level6.
Fig 1. Morphology of cardiac muscle cell during hypertrophy (Illustration from Epstein et al. 1999)
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Figure 1.
 
 Morphology of Ventricular Muscle Cells in Cardiac Hypertrophy and Failure.
Phenotypically distinct changes in the morphology of myocytes occur in response to various growth stimuli. The expression of
embryonic genes such as natriuretic peptides is increased in both eccentric and concentric hypertrophy, but not in physiologic hy-
pertrophy, in response to exercise. Myofibrillar disarray (sarcomeric disorganization) is typical of hypertrophic cardiomyopathies;
this disorganization is focal and is accompanied by more widespread increases in the cross-sectional area of myocytes.
 
*A more complete description of each of these classes has been published.
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1.1.1 Myocardial hypertrophy
Myocardial hypertrophy is an early milestone during the clinical course of heart failure and is an 
important risk factor for subsequent cardiac morbidity and mortality7. Myocardial hypertrophy 
occurs in response to a variety of physiological, mechanical, hemodynamic, hormonal, and 
pathologic stimuli. This forces the heart to augment output in the face of increased demands 
through the initiation of a hypertrophic response characterized by an increase in the contractile 
protein content of the individual cardiomyocytes without a concomitant proliferative response6,8. 
Hypertrophy can be classified as the following4: (1) physiological, which is associated with exercise 
or pregnancy; (2) pathological, which is associated with disease-inducing stimuli, and (3) 
developmental, which is associated with the normal growth of the heart after birth until adulthood. 
Developmental and physiological hypertrophy are characterized by eccentric hypertrophy with 
uniform growth of the ventricular wall and septum that is matched with an increase in chamber 
dimension. The increase in cardiomyocyte size occurs due to the addition of sarcomeres in series 
and in parallel to both lengthen the cell as well as increase the width of the cell. 
Pathological cardiac hypertrophy is characterized by concentric hypertrophy  in which the 
ventricular wall and septum thicken with a net decrease in ventricular chamber dimensions (Fig 2). 
This remodeling is associated with a greater increase in cardiac myocyte width than length (Fig 1 
and 2). However, pathological cardiac hypertrophy can also produce a phenotype of eccentric and 
dilatory cardiac growth where sarcomeres are predominantly added in series to individual myocytes 
(Fig 1 and 2). Apart from structural remodeling, pathological hypertrophy  is also characterized by 
metabolic and functional remodeling of the heart. These changes can lead to a shift  toward 
glycolytic metabolism, alterations in calcium handling and contractility, loss of myocytes with 
fibrotic replacement, systolic or diastolic dysfunction, electrical remodeling, and 
arrhythmogenesis9.
2
Fig 2: Types of cardiac hypertrophy (Illustration from Heineke et al. 2006)
1.1.1.1 Hypertrophic signaling cascades
The stimuli for cardiac hypertrophy can be categorized into the following4: (1) biomechanical 
stretch sensitive mechanisms or (2) neurohumoral mechanisms associated with the release of 
hormones, cytokines, chemokines and peptide growth factors. Ligands are sensed by  cardiac 
myocytes through an array  of membrane-bound G protein-coupled receptors (GPCRs), receptors 
that have intracellular tyrosine kinase domains or that have intracellular serine/threonine kinase 
domains, and gp130-linked receptors. Biomechanical signals are thought to be mediated through 
internal stress sensitive receptors that converge on to a set of intracellular signal transduction 
circuits leading to the hypertrophic growth response. This response can alter the gene expression 
profile in the nucleus by  increasing the rate of protein translation and slowing down the rate of 
protein degradation in the cytoplasm. During cardiac hypertrophy, there is an increase in expression 
fetal genes, including the genes for natriuretic peptides and fetal contractile proteins e.g. Nppa and 
Myh7, respectively. The induction of natriuretic peptide genes is considered to be a prognostic 
indicator of clinical severity7,8.
The signal transduction pathways involved in the hypertrophic response are inherently  complex and 
abundant. These include the mitogen-activated protein kinase (MAPK), calcineurin/nuclear factor 
of activated T cells (NFAT) and insulin like growth factor 1 (IGF1)-phosphatidylinositol 3-kinase 
(PI3K)–AKT/protein kinase B (PKB)–mammalian target of rapamycin (mTOR), regulation of 
© 2006 Nature Publishing Group 
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analysis of cardiac growth mechanisms. However, the 
more recent development of genetically modified mouse 
models has greatly advanced our understanding of the 
complexiti s that surrou d the ardiac growth response, 
and has provided a cornucopia of data regarding the 
potential molecular underpinnings of cardiac hyper-
trophy, ventricular remodelling and heart failure. Here, 
we first discuss how cardiac myocytes sense stress and 
ligands at the cell membran . Then, we consider a group 
of signal-transduction pathways that probably function 
as c ntral medi tors of the cardiac growth and r modell-
ing response. Many of these recently characterized 
signalling circuits predict novel therapeutic targets for 
treating various forms of heart disease.
Initiation of signalling at the cell membrane
The signalling events that occur at the cell membrane to 
initiate the cardiac hypertrophic response could easily be 
the subject of an entire review, although it will be briefly 
summarized here so that coupling with downstream 
pathways can be assembled in a logical context. 
Catecholamines (such as noradrenaline and adrenaline), 
endothelin-1, angiotensin II and IGF-I are well charac-
terized neuro umoral and e docrine hormones that are 
sensed through specific membrane-bound receptors on 
cardiac myocytes (FIG. 1).
Activation of G-protein-coupled receptors. Angiotensin II, 
endothelin-1 and catecholamines (α-adrenergic) bind to 
specific seven-transmembrane-spanning receptors that 
are coupled to heterotrim ric G proteins of the G
αq/α11 
subclass. These G proteins are coupled to phospholipase 
Cβ (PLCβ). This coupling induces the generation of 
diacyl glycerol (DAG), which functions as an intra cellular 
ligand for protein kinase C (PKC), leading to PKC acti-
vation, and production of inositol-1,4,5-trisphosphate 
(Ins(1,4,5)P3)14. Accumulation of Ins(1,4,5)P3 leads to 
the mobilization of internal Ca2+ by directly binding to the 
Ins(1,4,5)P3 receptor located in the endoplasmic reticulum 
or the nuclear envelope. Recently, the generation of 
Box 1 | Types of cardiac hypertrophy
Pathological cardiac hypertrophy is associated with ventricular remodelling through alterations in the extracellular 
matrix that eventually impact cardiac function and energy use121, and cause increased rates of myocyte cell death by 
apoptotic and necrotic mechanisms122. However, not all forms of cardiac hypertrophy are detrimental, as extensive 
aerobic conditioning through exercise induces a state of physiological growth that is thought to be adaptive in the long 
term12,123. Therefore, hypertrophy can be classified as ‘physiological’, which is associated with exercise or pregnancy, 
‘pathological’, which is associated with disease-inducing stimuli, and ‘developmental’, which is associated with the 
normal growth of the heart after birth until adulthood.
Developmental and physiological hypertrophy are characterized by a uniform profile of ventricular wall and septum 
growth that is matched with an increase in chamber dimension, referred to as eccentric hypertrophy (see figure). This 
phenotype is associated with cardiac myocyte hypertrophy in which sarcomeres are added in series to lengthen the cell, 
as well as on the periphery (that is, in parallel) to increase the width of the cell (cross-sectional area).
Pathological cardiac hypertrophy can produce concentric hypertrophy in which the ventricular wall and septum thicken 
with a net decrease in ventricular chamber dimensions (see figure). This remodelling is associated with a greater increase 
in cardiac myocyte width than length. However, pathological cardiac hypertrophy can also produce a phenotype of 
eccentric and dilatory cardiac growth. Cardiac dilation, although not typically referred to as hypertrophy, can result from 
a growth response in which sarcomeres are predominantly added in series to individual myocytes. The molecular 
underpinnings whereby sarcomeres ar  either added in series, in parallel or in  combination of both are not entirely 
understood. DCM, dilated cardiomyopathy; LV, left ventricle; RV, right ventricle.
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transcription by the cyclin-dependent kinase-7 (CDK7) and CDK9, and kinase-regulated shuttling 
of class II histone deacetylases (HDACs)4.
1.1.1.2 MAPK signaling in cardiac hypertrophy
The MAPK signaling cascade is initiated in cardiac myocytes by GPCRs, receptor tyrosine kinases 
(IGFI, and fibroblast growth factor receptors), receptor serine/threonine kinases (transforming 
growth factor-β (TGFβ)), cardiotrophin-1 (gp130 receptor), and by stress stimuli such as stretch. 
The MAPK signaling pathways link external stimuli and the nucleus by phosphorylating and 
thereby regulating multiple transcription factors. Based of sequence homology  MAPKs can be 
divided into three subfamilies namely, extracellularly  responsive kinases (ERKs), c-Jun N-terminal 
kinases (JNKs) and p38 MAPKs. JNKs and p38 MAPKs are also called stress responsive MAPKs 
because they are activated by stress stimuli like ischemia and hyperosmotic shock10. Activated p38, 
JNKs and ERKs each phosphorylate multiple intracellular targets, including numerous transcription 
factors that induce the reprogramming of cardiac gene expression4. ERK1 (also called MAPK3) and 
ERK2 (also called MAPK1) are part of MAPK cascade consisting of 3 sequentially  functioning 
kinases namely RAF, MAP2K and MAPK1/311. Once activated they reprogram gene expression by 
phosphorylating a variety  of intracellular proteins and transcription factors involved in various 
functions like growth, proliferation, differentiation, etc.
The upstream activators of MAPK1/3 are two MAPK kinases (MAP2K), MEK1 and MEK2, that 
phosphorylate a dual site (Thr-Glu-Tyr) in the activation loop of MAPK1/3. p38 kinases are directly 
activated by the MKK6 and MKK3 and JNKs are directly activated by MKK4 and MKK7. ERK5, 
also known as big MAPK1, is directly  activated by MEK512. Upstream of the MAP2Ks, several 
MAP2K kinases form a complex network of kinases that either directly sense stress stimulation or 
are regulated by  either MAPKKK kinases or the low molecular mass G proteins of the RHO family, 
RAS, RAC, RHO and CDC424. The primary MAPKKKs that activate MAPK1/3 are the RAF 
isoforms, A-RAF, B-RAF and C-RAF or RAF1. RAF is activated by the binding of small G 
proteins of RAS family to its N-terminus. RAF1 was initially identified as the MAP2K kinase in the 
MAPK1/3 pathway by its ability to activate MEK113. RAS is a low-molecular-weight GTPase that 
is activated by GDP to GTP exchange initiated by  the membrane bound receptors. It functions like a 
relay switch positioned downstream of cell surface receptor tyrosine kinases and upstream of a 
cytoplasmic cascade of kinases. Ras activation can lead to activation of RAF1, PI3K, small GTPase 
RAL proteins leading to RHO activation14. RAS can activate all three MAPK signaling cascades i.e 
MAPK1/3, JNK and p38 though RAF1 activation is associated only with activation of MAPK1/3.
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1.2 MicroRNAs
1.2.1 Discovery
MicroRNAs (miRNAs, miRs) are endogenous ≈22 nt RNAs that can play important regulatory 
roles in animals and plants by  targeting mRNAs for cleavage or translational repression15. Post-
transcriptional regulation by  a tiny regulatory  RNA was first described in Caenorhabditis elegans, 
where it was reported that  the gene lin-4 did not encode for a protein but instead produced a pair of 
small RNAs of approximately 22 and 61 nt long16. The longer 61 nt RNA was predicted to fold into 
a stem loop proposed to be the precursor of the shorter 22 nt RNA. These lin-4 RNAs had antisense 
complementarity to multiple sites in the 3’ UTR of the lin-14 gene16,17. These discoveries suggested 
a model of post  transcriptional regulation where the lin-4 RNAs paired to the 3’ UTR of lin-14 
mRNA and repressed the translation of the lin-14 message as part of a regulatory mechanism in the 
C. elegans larval development16,17. The shorter lin-4 RNA is the founding member of an abundant 
class of tiny regulatory RNA called microRNAs18-20.
1.2.2 Biogenesis
MicroRNAs are encoded in the genome either in the intergenic regions or within introns of other 
protein coding genes (Fig 3). MicroRNAs are transcribed by either RNA polymerase II or RNA 
polymerase III to form long precursor transcripts called primary microRNAs (pri-miRNAs) that can 
be several kilobases long21,22. Transcription by both polymerases follow different regulatory 
processes and recognize specific promoter elements23. A single pri-miRNA transcript  can encode 
several mature microRNAs. 
The pri-miRNA is endonucleolytically processed by the nuclear microprocessor complex formed by 
the RNase III enzyme Drosha and the DGCR8 (DiGeorge critical region 8) protein (also known as 
Pasha (Partner of Drosha) in D. melanogaster and C. elegans)24-28 leading to the excision of a 60-70 
nt stem-loop hairpin structure called precursor microRNA (pre-miRNA). DGCR8 functions as a 
molecular ruler to determine the precise cleavage site enabling Drosha to cleave 11 base pairs away 
from the single-stranded RNA/double-stranded RNA junction at the base of the stem loop27,29. 
The pre-miRNA is then exported into the cytoplasm by Exportin-5 (XPO5) and Ran-GTP30. The 
binding of Exportin-5 to pre-miRNAs is independent of their sequence or stem-loop structure. 
However, a defined length of the double stranded stem and 3’ overhang are important for a 
successful binding to Exportin-5 to ensure the export of only correctly processed pre-miRNAs31-33. 
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The pre-miRNAs then undergo cytoplasmic miRNA processing through RISC assembly. RISC 
(RNA induced silencing complex) is a cytoplasmic multiprotein complex composed of the RNase 
III Dicer, the double-stranded RNA-binding domain proteins TRBP (Tar RNA binding protein) and 
PACT (protein activator of PKR), and the core component Argonaute-2 (Ago2)34-37. MicroRNAs 
with a high degree of complementarity along the hairpin stem undergo an additional 
endonucleolytic cleavage step mediated by Ago-2 leading to the generation of a nicked hairpin 
producing the Ago2-cleaved precursor miRNA or ac-pre-miRNA38. The RNase III Dicer then 
cleaves the pre-miRNA or the nicked ac-pre-miRNA to generate a roughly 22 nt microRNA duplex 
with a 2 nt overhang at  the 3’ end. The deletion of Dicer can abolish or decrease the generation of 
mature microRNAs suggesting that Dicer-mediated cleavage is essential for microRNA 
processing39-42. Dicer and TRBP/PACT then dissociate from the duplex to allow the separation of 
the functional guide strand that is complementary to the mRNA target and the passenger strand that 
is subsequently  degraded. In principle the microRNA duplex could lead to two different mature 
microRNAs but usually  only one of them is functional while the other is degraded43. This strand 
bias depends on the thermodynamic stability of the bases at both the ends of the duplex i.e. the 
strand with less stable base pairs at its 5’ end becomes the functional guide strand44.
1.2.3 Mechanism of action
MicroRNAs can regulate gene expression by  inhibiting mRNA translation or stability  in the 
cytoplasm45,46. This process requires the presence of the Argonaute (AGO) family  of proteins, 
which are key components of the RISC. Mammals encode for four different AGO proteins, AGO1 
to AGO4. Of these four, only AGO2 possesses the ability to cleave mRNA at the center of the 
miRNA-mRNA duplex due to its RNaseH-like P-element induced wimpy testis (PIWI) domain47. 
MiRNA-mRNA interaction involves a contiguous and perfect pairing between the nucleotides 2-8, 
the so called seed region of the microRNA with complementary sites usually in the 3’ UTR of the 
target mRNA. GU pairs or mismatches and bulges in the seed region generally  affect the strength of 
repression. The site efficacy might be improved due to the presence of an A residue at  position 1 of 
the microRNA and an A or U across position 9. Mismatches in the seed region might be offset by 
good base pairing particularly  to residues 13-16 of the miRNA48. Binding of micro-
ribonucleoproteins (miRNPs) along with accessory  factors, to the 3′ UTR of the target mRNA can 
induce deadenylation followed by rapid decay of the mRNA49. The AGO1 protein can colocalize 
with mRNA degradation enzymes within P-bodies containing GW182 protein leading to mRNA 
decay50. Alternatively, the miRNPs can repress translation initiation at cap-recognition51 or the 60S 
6
ribosomal subunit joining stage52. The repression can also occur at post-initiation phases of 
translation due to slowed elongation53.
Fig 3 MicroRNA biogenesis
1.2.3 Functional relevance of microRNA action
MicroRNAs preferentially bind to the complementary regions within the 3’ UTR of their targets. 
Approximately  37% of microRNAs are encoded within the introns of other protein coding genes54. 
Among these miRs, a majority of them are cotranscribed and processed with their host genes55. This 
coprocessing of miRs and their protein coding host genes can often regulate important biological 
phenomena in a synergistic or antagonistic manner by  means of complex feedback or feedforward 
networks (Fig 4a)56,57. One well studied example involves the myosin heavy  chain genes and a 
family of intronic miRs encoded by them. The family includes miR-208a (encoded by  Myh6 or α-
MHC), miR-208b (encoded by Myh7 or β-MHC) and miR-499 (encoded by Myh7b)58-60. These 
7
miRs modulate a number of transcriptional repressors and signaling molecules governing the stress 
induced response of the heart. The deletion of miR-208a prevented the reactivation of the fetal β-
MHC during myocardial hypertrophy preventing the heart from pathological cardiac remodeling. α-
MHC is the predominant myosin isoform in the adult heart while β-MHC is predominantly 
expressed during embryonic development. However, cardiac stress induces the switching of α-MHC 
to β-MHC affecting cardiac function. It is known that microRNAs target several mRNAs, often at a 
modest level. This modest  regulation can however have significant effects when a microRNA 
targets multiple factors within a same biological process or signaling cascade (Fig 4b)56. This 
process may  add robustness to important gene regulatory networks. Another possibility is the 
combinatorial action of several microRNAs on one or more targets within a regulatory network (Fig 
4c). Such a cooperation of multiple microRNAs could increase redundancy and prevent the reliance 
on one single miR. Some microRNAs can act as physiological buffers repressing both positive and 
negative regulators of the same functional regulator (Fig 4d). An example of such a microRNA is 
the zebrafish miR-430 that  represses the expression of TGFβ agonist squint and antagonist lefty61. 
When repression of squint or lefty by miR-430 was inhibited using target protectors, the TGFβ 
nodal signaling was either enhanced or inhibited. When both squint and lefty were protected or 
miR-430 was inhibited an imbalance and reduction in the TGFβ signaling was observed suggesting 
that miR-430 acted like a physiological buffer balancing this signaling process.
8
Fig 4: Concepts of microRNA function (Illustration from Small et al. 2011)
1.3 Relevance of microRNAs in the heart
The heart  is the first organ to form during embryogenesis62. Formation of the heart involves a 
complicated orchestration of a series of events involving a number of genetic pathways regulated by 
multiple transcription factors and proteins63. MicroRNAs have added another dimension to this 
process by  being a part of nearly every stage of this process, from development and function to 
pathological remodeling. Deletion of Dicer results in a dramatic reduction of mature microRNAs in 
the heart leading to postnatal death of the mutant mice due to severe heart failure and dilated 
cardiomyopathy (DCM)64. These mice show misexpression of cardiac contractile proteins, profound 
sarcomere disarray, significantly reduced heart rates and decreased fractional shortening, all of 
which allude to the critical role played by microRNAs in normal cardiac function and under 
pathological conditions. Similarly, conditional Dicer gene deletion in the myocardium of both 
juvenile mice results in premature death within a week65. In adult mice, the conditional loss of 
oligonucleotides directed against specific miRNA sequences are effi-
ciently taken up by a variety of tissues and block miRNA function in 
the heart and vasculature18. 
Other oligonucleotide-based techniques involve ‘target protectors’ or 
‘masks’, which block individual miRNAs from binding to their mRNA 
targets, thereby rescuing the mRNA from inhibition. Target protectors 
have been validated in zebrafish35 and in cultured cardiac myocytes36. 
miRNA ‘sponges’ or ‘decoys’ containing several miRNA-binding sites 
also act as competitive inhibitors for miRNA binding37,38. Although the 
results obtained from pharmacological knockdown or overexpression 
of miRNAs sometimes differ from those obtained using genetic mouse 
models, the development of these various technologies has greatly accel-
erated the rate at which basic biological questions can be answered in 
an experimental setting. 
miRNAs in cardiovascular development
The requirement of miRNAs for cardiovascular development and 
function was initially demonstrated by tissue-specific deletion in 
mice of the Dicer gene, which encodes an enzyme that is essential 
for miRNA processing. Lethal phenotypes were observed after Dicer 
deletion in myocardial and vascular lineages39,40. Although these 
findings highlight the crucial roles of miRNAs in the cardiovascular 
system, no specific miRNA deletion has yet been found to cause 
fully penetrant embryonic lethality in mice, indicating significant 
redundancy of miRNA function28 and suggesting that the lethal con-
sequences of Dicer deletion reflect the collective functions of many 
miRNAs rather than any single miRNA. The rapidly expanding 
number of miRNAs implicated in various aspects of cardiovascular 
biology precludes an in-depth review of all of them, so general prin-
ciples of miRNA regulation and function are considered throughout 
this Review.
Roles of miRNAs in heart development
Heart formation requires precise and complex interactions among 
diverse cell types from several lineages — cardiomyocytes, endocar-
dial, epicardial and vascular cells, fibroblasts and cells of the conduction 
system. Specific miRNAs are enriched in different cardiac cell types and, 
in some cases, have been found to participate in the specification of 
cell identity. Genetic ablation and antisense oligonucleotide-mediated 
knockdown studies have shown miRNA contributions to developmental 
processes as diverse as embryonic stem (ES)-cell differentiation, cardio-
myocyte proliferation, contractility, ion-channel regulation and cardiac 
conduction (Fig. 3). 
Expression profiling has shown that the 18 most abundant 
miRNAs in the heart account for more than 90% of all cardiac miRNAs41. 
Because a threshold level of miRNA expression seems to be required for 
the efficient repression of target gene expression (typically >100 copies 
per cell)37,42, the regulation of heart development may depend on either 
a relatively discrete set of miRNAs or the combinatorial function of a 
larger array of miRNAs expressed at a low level. So far, a functional role in 
heart development has been ascribed to only the most enriched miRNAs, 
reflecting a dosage requirement, functional redundancy or both.
miR-1 is the most abundant miRNA in cardiac myocytes, and it was 
the first miRNA implicated in heart development30. miR-1 and the 
related miRNA miR-133 arise from a common precursor RNA, the 
expression of which in the embryonic heart is mediated by two sepa-
rate enhancers that are regulated by the transcription factors SRF and 
MEF2 (refs 43, 44), integrating these miRNAs into well-characterized 
transcriptional networks. miR-1 and miR-133 seem to function coop-
eratively to promote mesoderm differentiation of ES cells and suppress 
endodermal and ectodermal cell fates45. By contrast, they have opposing 
roles later in the cardiac lineage when miR-1 promotes and miR-133 
inhibits cardiomyocyte differentiation45. Neither miR-1 nor miR-133 is 
absolutely required for the specification of cardiac cell fates in vivo, as 
50% of mice lacking either miRNA are viable30,46. This disparity between 
the functions of miRNAs as determined by in vitro assays versus in 
vivo loss-of-function studies is a common theme, and suggests that 
compensatory mechanisms that account for the unexpectedly mild 
phenotypes may be activated in genetic knockout mice. Zebrafish seem 
to be particularly sensitive to miRNA regulation, such that inhibition 
of specific miRNAs evokes more dramatic phenotypes than those 
seen in mutant mice. For example, antisense-mediated knockdown of 
miRNAs in zebrafish has revealed roles for miRNAs in the formation of 
the cardiac chambers and the atrioventricular canal47,48. 
Roles of miRNAs in vascular and blood development
The formation and function of the vascular system requires the estab-
lishment and remodelling of a contiguous series of lumenized tubes 
made of endothelial cells. Concurrent recruitment of vascular smooth 
muscle cells (SMCs) to the endothelial plexus during vessel matura-
tion imparts the necessary tone and contractility for proper blood flow. 
Numerous miRNAs have been shown to govern these processes during 
vascular development and disease (Fig. 4). 
The endothelial-cell-specific miRNA miR-126 is encoded by an 
intron of the epidermal growth factor-like domain 7 (Egfl7) gene, 
which encodes an endothelial-cell-enriched growth factor involved in 
the control of cell migration49. miR-126 is induced by blood flow and 
controls angiogenic sprouting of aortic arch vessels by the stimulation 
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Dicer induced spontaneous cardiac remodeling along with profound biventricular enlargement, 
myocyte hypertrophy, myofiber disarray, ventricular fibrosis and strong induction of fetal gene 
expression. This further demonstrates the importance of microRNAs indicating that modifications 
in their biogenesis has major cardiovascular implications.
Two highly expressed microRNAs in the heart are miR-1 and miR-133 that are clustered together 
on the same chromosomal loci66. There two miR-1 variants, miR-1-1 and miR-1-2 and 3 miR-133 
variants, miR-133a-1, miR-133a-2, miR-133b. Deep sequencing of microRNAs in the heart show 
that miR-1 is the most highly  expressed microRNA accounting for 40% of all microRNAs67. MEF2 
and SRF cooperatively regulate the two bicistronic microRNA clusters encoding miR-133a-1/
miR-1-2 and miR-133a-2/miR-1-1 in cardiac and skeletal muscle68,69. The two miR-1 variants, 
miR-1-1 and miR-1-2 are cardiac and skeletal-muscle specific and are expressed in a chamber 
specific manner during cardiogenesis68. Both variants are direct targets of muscle differentiation 
factors SRF, myocardin and MEF2 thus negatively regulating ventricular cardiomyocyte 
proliferation70. MiR-1 directly  targets the transcription factor Hand2 that promotes ventricular 
cardiomyocyte expansion and titrates the level of regulatory proteins to balance differentiation and 
proliferation during cardiogenesis. The targeted deletion of miR-1-2 in mice leads to a spectrum of 
abnormalities like ventricular septal defects leading to early  lethality or cardiac rhythm disturbances 
and myocyte hyperplasia71. Similarly, the deletion of miR-133a-1 and miR-133a-2 in mice causes 
lethal ventricular septal defects in half of the mutant embryos and the rest die from DCM and heart 
failure72. The absence of miR-133a expression results in ectopic expression of smooth muscle genes 
in the heart and aberrant  cardiomyocyte proliferation due to elevated expression of miR-133a 
targets, SRF and cyclin D2.
1.3.1 MicroRNAs in the failing heart
Heart failure is associated with common histological features of myocyte hypertrophy  and death, 
due to compensatory pathological remodeling and minimal functional repair with microRNA 
involvement. Pathological cardiac remodeling induces a signature pattern of stress responsive 
microRNAs leading to cardiac hypertrophy and heart failure73,74. MiR-1 and miR-133 are both 
downregulated in cardiac hypertrophy75,76. MiR-1 directly targets a number of growth promoting 
factors like Ras GTPase activating protein (RASA1), cyclin-dependent kinase 9 (CDK9), Ras 
homolog enriched in brain (RHEB), and fibronectin that are upregulated upon miR-1 
downregulation during induction of hypertrophy75, Overexpression of miR-133 or miR-1 in vitro 
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inhibited cardiac hypertrophy  while antagomir based inhibition of miR-133 in vivo caused marked 
and sustained cardiac hypertrophy76. MiR-133 also targets several proteins like Ras Homolog 
Family Member A (RHOA), Cell division control protein 42 homolog (CDC42) and Negative 
elongation factor A (NELFA). 
The loss of a cardiac specific microRNA, miR-208, in mice during pressure overload, protected 
them against cardiac hypertrophy and upregulation of β-MHC induced hypothyroidism due to the 
activation of calcineurin signaling59. MiR-21 is one of the most significantly  upregulated miRNAs 
in cardiac hypertrophy73. AntagomiR-21 based intervention results in antihypertrophic and 
antifibrotic effects and improved function following hypertrophic stress due to reduced activation of 
ERK/MAPK cascade77. Another microRNA family namely, the miR-199 family of miRNAs are 
also upregulated in cardiac hypertrophy78. MiR-199b is induced by  prohypertrophic calcineurin/
NFAT signaling cascade in mouse and human heart failure and targets the nuclear NFAT kinase 
dual-specificity  tyrosine-(Y)-phosphorylation regulated kinase 1a (DYRK1A)79. Overexpression of 
miR-199b in mice show reduced DYRK1A expression with increased sensitivity to pressure 
overload and calcineurin/NFAT signaling. Antagomir based inhibition of miR-199b in vivo reduced 
NFAT activity and reversed hypertrophy and fibrosis. Hence miR-199b is part of a pathogenic 
feedforward mechanism involved in pathological cardiac hypertrophy.
1.4 MicroRNA-378
MiR-378 is encoded within the first intron of the gene Ppargc1b (Fig 5). The 3’ strand of the 
microRNA was reported to be the predominant  one compared to the 5’ strand and was initially 
annotated as miR-422b80 and was later renamed as miR-378 or miR-378-p and correspondingly  the 
opposite strand was annotated as miR-378* or miR-378-5p. In humans, 11 variants of miR-378 
have been annotated so far (called miR-378a-3p/b/c/d/e/f/g/h/i/j and miR-422a). These variants are 
encoded by different genomic loci but share identical seed sequences. MiR-378 family of miRs are 
evolutionarily conserved between humans and several other species. 
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Fig 5: Schematic representation of the Ppargc1b locus indicating the location of miR-378 in  the first 
intron and its evolutionary conservation.
Initial studies with miR-378 show that it functions as an oncogene by promoting tumor growth and 
angiogenesis81. Overexpression of miR-378 in grafts of glioblastoma cells enhanced cell survival, 
reduced caspase-3 activity and repressed two tumor suppressors, suppressor of fused homolog 
(SUFU) and fused in sarcoma 1 (FUS1) leading to increased growth and vascularization of tumors. 
Interestingly, in this study  the authors studied the 5p strand i.e. miR-378-5p. miR-378 also promotes 
oncogenic cellular transformation in vitro by targeting and repressing the antiproliferative 
transcription factor TOB2 that represses the proto-oncogene cyclin D182. The transcription factor c-
Myc activates a complex cascade of targets including miR-378 ultimately leading to cellular 
transformation through the functional module of miR-378-TOB2-cyclin D1 that mediates the cross 
talk between Myc and RAS signaling. 
The role of miR-378 in the heart is currently not completely clear. Two in vitro studies describe 
conflicting roles of miR-378 in apoptosis. MiR-378 is significantly  downregulated in myocardial 
infarction in rat83. Overexpression of miR-378 in H9C2 cells attenuated ischemia-induced apoptosis 
by inhibiting caspase-3. The second study  focussed on primary neonatal rat cardiomyocytes, where 
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overexpression of miR-378 increased apoptosis by direct  targeting of IGF1R and reduced signaling 
in the AKT cascade84. Also, the inhibition of miR-378 using antimir protected the myocytes against 
H2O2 and hypoxia reoxygenation-induced cell death by promoting IGF1R expression and AKT 
signaling cascade. 
1.5 MicroRNA therapeutics
MicroRNAs have prominent biological functions and form an intrinsic part of cardiovascular 
function. Manipulation of microRNA expression and function in the body by means of mimics, 
recombinant viral vectors or antagomirs can have profound therapeutic affect. A promising means 
of enhancing microRNA expression or replacing downregulated microRNAs is through adeno-
associated viruses (AAVs). The availability of a variety of AAV serotypes with varying degrees of 
tissue enrichment due to their natural tropism towards different tissues and cell types based the 
presence of specific cellular receptors85. AAV type 6 and type 9 have been described to display 
tropism for skeletal muscle and heart respectively86.
1.5.1 Adeno-associated viruses
AAVs are human parvoviruses. They are nonpathogenic, non enveloped DNA viruses containing a 
linear single stranded genome of 4.6 - 4.8 kb and require coinfection with a helper virus for viral 
replication87,88. During infection the AAV DNA gets uncoated and converted to a duplex form that is 
then integrated into the host cellular DNA in a site specific manner89. The AAV genome contains 
two open reading frames encoding alternatively  spliced capsid (Cap) proteins and multifunctional 
replication (Rep) proteins and are flanked by 145 base pair inverted terminal repeats (ITRs)90,91. 
Recombinant AAVs for targeted gene transfer can be generated through a plasmid vector containing 
the therapeutic gene cassette flanked by  the ITRs with the total size of less than 5 kb for efficient 
packaging. The recombinant  AAVs have been shown to persist  for extended durations in the form of 
episomes after transduction92. The absence of viral coding sequences renders AAV vectors highly 
suitable gene targeting vehicles due to limited toxicity  or inflammatory responses except for the 
generation of neutralizing antibodies that may limit re-administration90.
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1.6 Aim of the study
The aim of this study was to characterize the role of miR-378 in cardiomyocytes and its relevance 
in the diseased myocardium. To this end, the following points were investigated:
1. Expression profiling: The expression of miR-378 was investigated in human and mouse 
myocardium in physiological as well as diseased state. MiR-378 expression was also determined 
in isolated myocardial cells namely, cardiomyocytes and cardiac fibroblasts.
2. Relevance in cardiac hypertrophy: The relevance of miR-378 in cardiomyocyte hypertrophy was 
investigated by  the overexpression of synthetic miR-378 mimics and by the inhibition of 
endogenous miR-378 in primary cardiomyocytes. An in vivo mouse model of pressure overload 
hypertrophy was used to investigate the role of miR-378 in mouse hearts.
3. Determination of miR-378 targets: Targets of miR-378 were determined using expression 
profiling and confirmed by studying the regulation of their mRNA and protein levels. Direct 
interaction of these targets with miR-378 was determined through 3’ UTR reporter assays with 
native and mutated miR-378 binding sites. The functional relevance of the targets of miR-378 in 
cardiac hypertrophy was determined using shRNA and siRNA-based interference in primary 
cardiomyocytes. 
4. In vivo relevance of miR-378: The physiological role miR-378 was investigated in a pressure 
overload mouse model of hypertrophy by cardiotropic overexpression of miR-378 using adeno-
associated virus 9. The resulting effect on cardiac hypertrophy and cardiac function as well as on 
the targets of miR-378 was investigated.
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2 MATERIALS
2.1 Antibodies
Epitope Host Reference
Anti-KSR1
Anti-MAPK1/3
Anti-PhosphoMAPK1/3
Anti-IGF1R
Anti-GRB2
Anti-HSP90
Anti-α-Actinin
HRP-anti-mouse IgG 
(Secondary antibody)
HRP-anti-rabbit IgG 
(Secondary antibody)
AlexaFluor 488 anti-mouse IgG 
(Secondary antibody)
Mouse #611576, BD Biosciences
Rabbit #9102, Cell Signaling
Rabbit #9101, Cell Signaling
Rabbit #3027, Cell Signaling
Rabbit #3972s, Cell Signaling
Mouse sc-13119, Santa-Cruz
Mouse A7811, Sigma-Aldrich
Goat 115-035-003, Jackson 
Immunoresearch Laboratories
Goat 111-035-144, Jackson 
Immunoresearch Laboratories
Goat A11029, Life Technologies
2.2 Bacterial strains
Strain Genotype Manufacturer
E. coli DH10B 
(Electrocompetent)
F- mcrA ∆(mrr-hsdRMS-mcrBC) φ80lacZ ∆M15 
∆lacX74 recA1 endA1 araD139 ∆(ara, leu)7697 galU 
galK λ - rpsL nupG tonA
Life Technologies
2.3 Buffers and media
BSA Blocking buffer: Tris-HCl pH 7.5  50 mM
    NaCl    150 mM
    BSA    2% (m/v)
    Nonidet P40   0.2% (v/v)
    NaN3    0.03% (m/v)
BSA Washing buffer:  Tris-HCl pH 7.5  50 mM
    NaCl    150 mM
    BSA    0.5% (m/v)
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    Nonidet P40   0.2% (v/v)
CBFHH medium:  NaCl    137 mM
    KCl    5.36 mM 
    MgSO4.7H2O   0.81 mM 
    Dextrose   5.55 mM 
    KH2PO4   0.44 mM
    Na2HPO4.7H2O  0.34 mM
    Adjust pH to 7.3
BrdU stock:   BrdU    230 mg
    ddH2O    74.8 ml
DNA loading buffer (5x): Xylene cyanol   10 g
    0.5 M EDTA    1.4 ml
    Glycerol   3.6 ml
    ddH2O    up to 1 l
Laemmli buffer (2x):  Tris-HCl 1M pH 6.8  12.5 ml
    SDS 10%   40 ml
    Glycerol   30 ml 
    β-mercaptoethanol  1 ml 
    Bromophenol blue  traces
LB agar:   Peptone   10 g
    Yeast extract   5 g
    NaCl    5 g
    Agar    15 g
    1 M NaOH   1 ml
    ddH2O    up to 1 l
  
LB medium:   Peptone   10 g
    Yeast extract   5 g
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    NaCl    5 g
    1 M NaOH   1 ml
    ddH2O   up to 1 l
Lower buffer 4x:  Tris    182 g
    SDS 10%   40 ml
    ddH2O    up to 1 l
    Adjust pH to 8.8 with HCl 
NRCM incomplete medium: MEM     10.7 g
    NaHCO3   0.35 g
    Vitamin B12 67% (w/v) 1 ml
    ddH2O    up to 1 l
    Adjust pH to 7.3 and sterile filtered the solution
NRCM pre-plating medium: NRCM incomplete medium 94 ml
    Penicillin/Streptomycin 1 ml
    FCS    5 ml
NRCM culturing medium: NRCM incomplete medium 93 ml
    Penicillin/Streptomycin 1 ml
    FCS    5 ml
     BrdU stock   1 ml
P1 buffer:   Tris    50 nM
    EDTA    10 nM
    pH 8.0
    Rnase I (after autoclaving) 100 mg 
P2 buffer:    NaOH    200 mM
    SDS    1%
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P3 buffer:   Potassium acetate  3M
    pH 5.5
PBS (10x):   NaCl    80 g
    KCl    2 g    
     Na2HPO4.7H2O  11.5 g 
    KH2PO4   2 g
    ddH2O    up to 1 l
Running buffer (10x): Tris-HCl   30 g
    Glycine   144 g
    SDS    15 g
    ddH2O    up to 1 l
SDS lysis buffer:  Tris (1M pH 6.7)  50 mM
    SDS    2 %
    Na3VO4   1 mM
    Complete mini  1 tablet per 10 ml
    PhosStop   1 tablet per 10 ml
Sirius Red solution(0.01%): Direct Red 80   50 mg
    ddH2O    15 ml
    Sterile filteration
    Piric acid-solution 1.3% 485 ml
TAE buffer (50x)  Tris    242 g
    Acetic acid   57.1 ml
    Na2EDTA.2H2O  37.2 g
    ddH2O    up to 1 l
Transfer buffer  Tris (1M pH 8.3)  25 ml
    Glycine   11.26 g
    Methanol   100 ml
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    ddH2O    up to 1 l
Upper buffer (4x):  Tris    61 g
    SDS 10%   40 ml
    ddH2O    up to 1 l
    Adjust pH to 6.7 with HCl
2.3 Chemicals
The chemicals used in this study were obtained from AppliChem, Carl Roth, Merck and Sigma-
Aldrich unless otherwise mentioned. 
2.4 Enzymes
Kit Manufacturer
Accuprime Pfx DNA Polymersase
Benzonase
Collagenase II
Difco Trypsin 250
DNase
Gateway BP Clonase II Enzyme mix
Gateway LR Clonase II Enzyme mix
Platinum Taq DNA Polymerase
Proteinase K
Restriction Endonucleases 
Superscript II Reverse Transcriptase 
T4 DNA Ligase 
Trypsin 
Trypsin 1:250 
Life Technologies
Merck
Worthington
BD Biosciences 
Sigma-Aldrich
Life Technologies
Life Technologies
Life Technologies
Fermentas
New England Biolabs
Life Technologies
New England Biolabs
Gibco
PAN
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2.5 Kits
Kit Manufacturer
Adeno-X purification kit
Adeno-X Rapid titer kit
BCA Protein assay kit
BLOCK-iT U6 RNAi Entry vector kit
ECL plus
Plasmid Maxi/Endofree Maxi kit
Promega Dual Luciferase assay kit
TaqMan MicroRNA assay (hsa-miR-378a-3p)
TaqMan MicroRNA assay (hsa-miR-1)
TaqMan MicroRNA assay (hsa-miR-133a)
TaqMan MicroRNA assay (U6 snRNA)
TaqMan MicroRNA Reverse Transcription kit
TaqMan Universal PCR Master Mix, No 
AmpErase UNG
SYBR Green qPCR Master mix
QIAquick Gel Extraction kit
In situ Cell Death Detection kit, Fluorescein
QuikChange II Site directed Mutagenesis kit
Clontech 
Clontech 
Thermo Scientific
Life Technologies
Thermo Scientific
Qiagen
Promega
Life Technologies
Life Technologies
Life Technologies
Life Technologies
Life Technologies
Life Technologies
Roche
Qiagen
Roche
Stratagene
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2.6 Plasmids*
Vector Insert Reference
pENTR/U6
pAd/CMV/V5-DEST30
pAD-BlockIT-Dest
pAD-BlockIT-Dest
pAd/CMV/V5-DEST30
pmiR-RL-TK2
pmiR-RL-TK2
pmiR-RL-TK2
pmiR-RL-TK2
pmiR-RL-TK2
Life Technologies
Life Technologies
Life Technologies
shRNA-Mapk1 pAd-adeno-shMapk1
shRNA-control pAd-adeno-shctrl
Gunter Meister (University of 
Regensburg)
Mapk1 3’ UTR (Rat) pmiR-RL-Mapk1
Igf1r 3’ UTR (Human) pmiR-RL-Igf1r
Ksr1 3’ UTR (Human) pmiR-RL-Ksr1
Grb2 3’ UTR (Human) pmiR-RL-Grb2
2.6 Primers†
The following oligonucleotide primers were obtained from MWG Eurofins and diluted with 
nuclease free water to a stock concentration of 1 mM.
Gene Sequence (5’ - 3’)
Nppa
Nppb
Myh7
Actb
Mapk1
Igf1r
CTCCCAGGCCATATTGGAǴ (forward) 
TCCAGGTGGTCTAGCAGGTT (reverse)
TGGGAAGTCCTAGCCAGTCTC (forward) 
TCTGAGCCATTTCCTCTGAĆ (reverse)
GGATGACGTTACCTCCAACA (forward) 
GTGTCTCCTCAGCCTTGCTC (reverse)
CTCTGAACCCTAAGGCCAAC (forward) 
ACCAGAGGCATACAGGGACA (reverse)
TCTCCCGCACAAAAATAAGG (forward) 
GCCAGAGCCTGTTCAACTTC (reverse)
AGCCATGGTGAGAAGACC (forward)  
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* These plasmids were published in Ganesan et al. Circulation 2013 (169)
† These primers were published in Ganesan et al. Circulation 2013 (169)
Gene Sequence (5’ - 3’)Igf1r
Grb2
Ksr1
Med13
Crat
shRNA-Mapk1
Mapk1 3’ UTR 
(native)
Mapk1 3’ UTR 
(Mutated)
Igf1r 3’ UTR 
(native)
Igf1r 3’ UTR 
(Mutated)
Ksr1 3’ UTR 
(native)
Ksr1 3’ UTR 
(Mutated)
Grb2 3’ UTR 
(native)
CGCACACGCCTTTGTAGTAG (reverse)
GGGGATTTCTCCCTGTCAGT (forward) 
CTGTTCTATGTCCCGGAGGA (reverse)
CCAAGGCCCTAACCAAGAAG (forward) 
GGAAGTTGAACCTGCTGTCC (reverse)
TTTACCACCTCAACTTCCAAA (forward) 
AAGGCTTCTTACACTGCACCA (reverse)
AACGCCTACAGAAGGGACTG (forward) 
GGGCTGGAGTAGATGACCAC (reverse)
CACCGTATTATGACCCAAGTGATGAGCGAACTCATCA
CTTGGGTCATAATA (top strand) 
AAAATATTATGACCCAAGTGATGAGTTCGCTCATCACT
TGGGTCATAATAC (bottom strand)
AAAAAAACTAGTTTCTTGACCCTGGTCCTGT (forward) 
TTTTTTGAGCTCCCACTGCATCTTTCAAAC (reverse)
CTTTCACGGAATTCTTCAACGTCGAGAGTTCTCCTGC
ACCAGGCCCTG (forward) 
CAGGGCCTGGTGCAGGAGAACTCTCGACGTTGAAGA
ATTCCGTGAAAG (reverse)
TCACTCATTTTTATGTCCCAC (forward)
TTTTTTGAGCTCACAAACATTTTATAA (reverse)
CACTCATTAGCGTTTTCAATAGGGCTCTTAAACGTCGT
AGATTACGGGTAGTCAGTTGACGAAGATCTGG 
(forward) 
CCAGATCTTCGTCAACTGACTACCCGTAATCTACGAC
GTTTAAGAGCCCTATTGAAAACGCTAATGAGTG 
(reverse)
AAAAAAACTAGTATTCTTGTTTTTG (forward)
TTTTTTGAGCTCATGGCCAAC (reverse)
GGTTTGGCTTGGGCGTCCTGGAACGTAGTAATCCAAA
GATGTAGCCAGCC (forward) 
GGCTGGCTACATCTTTGGATTACTACGTTCCAGGACG
CCCAAGCCAAACC (reverse)
AAAAAAACTAGTCTGCCTCCCTTCAGTGTCTC 
(forward) 
AAAAAAGAGCTCCTGCCAGCTCCTTTCTCTGT 
(reverse)
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Gene Sequence (5’ - 3’)
Grb2 3’ UTR 
(Mutated)
GAGTGGTGTCTTTACCTTTTTTATTTTTTTAAATAAGTT
AAAGATAACGTCGAGCTTTTCAGTTGATTAGTCTCCT
ATCCTATGTACATATTTTCCTCTCAGGGCAGGAGAAAG
AGG (forward) 
CCTCTTTCTCCTGCCCTGAGAGGAAAATATGTACATAG
GATAGGAGACTAATCAACTGAAAAGCTCGACGTTATC
TTTAACTTATTTAAAAAAATAAAAAAGGTAAAGACAC
CACTC (reverse)
2.6 Small interfering RNAs (siRNAs)‡
The following cocktail of ON-TARGETplus SMARTpool siRNAs were ordered from Thermo 
Scientific:
Gene Name Target Sequence 
Mapk1 (Rat)
Ksr1 (Rat)
Igf1r (Rat)
Grb2 (Rat)
si-Mapk1 ACACUAAUCUCUCGUACAU 
AAAAUAAGGUGCCGUGGAA 
UAUACCAAGUCCAUUGAUA 
UCGAGUUGCUAUCAAGAAA
si-Ksr1 GAGUUAGGCACUACGCAAA 
CCACUAAUAGGGACCGUUA 
GGGAAGGAGUAAAGCGUGU 
GUGAUGAACUACCGGCAGA
si-Igf1r GGGCCAAACUUAACCGUCU 
CCGGAUAACUGCCCCGAUA 
GGGAAAAUGUACUUCGCUU 
CAACAGGACACUCGAGAAU
si-Grb2 ACUCCAAUGACUUCGUAAA 
CAGUGAACCGGAACGUCUA 
GCCUCUAACUUCUGCGAAU 
GGACUAGAGGAGCCGGAUU
2.6 Viruses
Vector Insert Virus Final construct Reference
pAD-BlockIT-
Dest
pAd/CMV/V5-
DEST30
shRNA-
Mapk1 Adenovirus Adeno-shMapk1
shRNA-
control Adenovirus Adeno-shctrl D. Ramanujam 
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‡ These siRNAs were published in Ganesan et al. Circulation 2013 (169)
Vector Insert Virus Final construct Reference
pAAV-MCS-
Adapted
pAAV-MCS-
Adapted
hsa-miR-378a
Adeno associated 
virus 9 (AAV9)
AAV9-CMV-
miR-378 
L. Zentilin (ICGEB, 
Trieste, Italy)
GFP
Adeno associated 
virus 9 (AAV9)
AAV9-CMV-GFP
3 METHODS§
3.1 Cell culture
3.1.1 Isolation of neonatal rat cardiomyocytes *
Neonatal rat  cardiomyocytes (NRCM) were isolated from 1 – 2 day old Sprague Dawley rat pups 
using Collagenase II and Pancreatin enzymes. The isolation procedure was performed under sterile 
conditions. Briefly, the hearts from the pups were explanted and placed on ice in a tube containing 
15 ml of ice cold CBFHH. After trimming away  the vessels and atria, the hearts were minced using 
micro scissors by cutting each heart 7 – 12 times. The minced hearts were then transferred to a 50 
ml beaker with 15 ml enzyme solution (0.6 mg/ml Pancreatin and 0.4 mg/ml Collagenase II), 
covered and placed in a shaker set at  37°C with constant shaking at 220 rpm for 5 minutes. After 5 
minutes the enzyme solution was discarded since it mostly contained erythrocytes. Serial digestions 
were then performed first for 20 minutes, second and third for 25 minutes, fourth for 15 minutes 
and finally the fifth digestion for 10 minutes. After each digestion the cell suspension was 
immediately mixed with 2 ml FCS and centrifuged at 1200 rpm for 5 minutes. The resulting pellet 
was suspended in 4 ml FCS and incubated at 37°C/1% CO2. After performing all the serial 
digestions, the FCS suspension containing all the cells were centrifuged again at 1200 rpm for 5 
minutes. The resulting pellet was resuspended in 10 ml pre-plating medium and filtered (40 µM 
pore size, BD). The filtrate was then mixed in 40 ml pre-plating medium (pre warmed to 37°C). 
Approximately  15 ml of the medium containing cells was plated onto a 10 cm dish and incubated 
for 90 minutes at 37°C/1% CO2 to enable the separation of cardiomyocytes and cardiac fibroblasts. 
During pre plating the cardiac fibroblasts adhere to the cell culture dish while the cardiomyocytes 
stay in the supernatant. After 90 minutes the supernatant containing cardiomyocytes is collected in a 
50 ml tube and the cardiomyocyte number is quantified by  mixing 50 µl cell suspension with 50 µl 
Tryphan blue. 10 µl of this mixture is used to quantify the cell number (Countess cell counter, Life 
24
§ Parts of this section were published with some modifications in Ganesan et al.Circulation 2013 (169)
* Protocol modified from Abcam
Technologies). The cells are then mixed in 5% NRCM  medium and plated as required and 
incubated at 37°C/1% CO2.
3.1.2 MicroRNA transfection
MicroRNA transfection was performed one day after isolation of primary  neonatal rat 
cardiomyocytes. Prior to the transfection procedure, the medium was exchanged to 5% FCS 
containing NRCM medium without antibiotics. 50 nM  of miR-378 mimic or antimiR-378 along 
with their respective controls was transfected into NRCM using Lipofectamine 2000. The medium 
was exchanged to 0.1% FCS containing NRCM medium after 6 hours. 
3.2 RNA Analysis
3.2.1 Isolation of RNA
RNA was isolated from NRCM and myocardium using TriFast  (Peqlab) according to the 
manufacturer’s instruction. The resulting RNA pellet was suspended in nuclease free water and the 
concentration was determined using Nanodrop spectrophotometer ND1000 (Peqlab).
3.2.2 Reverse transcription
The Reverse transcription-PCR (RT-PCR) is the preferred technique used to detect and quantify 
mRNA. The first part of the reaction, reverse transcription, synthesizes cDNA from RNA. The 
second step amplifies the synthesized cDNA to easily  detectable levels. To reverse transcribe the 
poly(A)-containing mRNAs, Oligo (dT) primers (MWG) were used to prime reverse transcription 
reactions for cDNA synthesis. A control reaction (RT control) with RNA pooled from all the 
samples, excluding Reverse transcriptase was also included. The resulting cDNA was then used for 
quantitative real time PCR analysis. The following procedure was used for the cDNA synthesis:
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Reagent Volume
RNA 1 µg
Oligo(dT) primer (10mM) 2 µl
Nuclease free water upto 11.9 µl
Incubation for 10 minutes at 70°C
5x First strand buffer 4 µl
0.1M DTT 2 µl
10mM dNTPs 1 µl
RNase Inhibitor 0.1 µl
Reverse transcriptase 1 µl
Incubation for 1 hour at 42°C
Incubation for 10 minutes at 70°C
Nuclease free water upto 100 µl (10 ng/µl concentration)
3.2.3 Quantitative real time PCR
Quantitative real time PCR follows the general principle of polymerase chain reaction; its key 
feature is that the amplified DNA is quantified as it  accumulates in the reaction in real time after 
each amplification cycle. Two commons methods of quantification are the use of fluorescent dyes 
(SYBR Green) that intercalate with double-stranded DNA and modified DNA oligonucleotide 
probes (TaqMan probes) that fluoresce when hybridized with a complementary DNA.
3.2.3.1 SYBR Green-based real time PCR
To detect mRNA regulation, quantitative real time PCR was performed with SYBR Green as the 
detected fluorophore and ROX as the passive reference dye. In the PCR reaction, the unbound SYBR 
Green exhibits little fluorescence. The fluorescence is substantially enhanced when the dye is bound 
to double stranded DNA. The threshold cycle (Ct) reflects the cycle number at which the 
fluorescence generated within a reaction crosses the threshold. The comparative Ct method was 
used to quantify  the results of the PCR. An average Ct value was first calculated from triplicate 
reactions, which was then normalized (to adjust for differences in the amount of cDNA in each 
reaction) to average Ct values of a control gene. The comparative Ct method is also known as the 
2-∆∆Ct method, where ∆∆Ct = ∆Ct,sample - ∆Ct,reference. The reactions were stored on ice during the 
preparation of the PCR plate. Each reaction was performed in triplicate. Along with the samples, 
two additional control reactions were also included during every PCR. First, was a no transcript 
control i.e a reaction with water instead of cDNA and second, a reverse transcription control (RT 
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control) i.e control reaction from reverse transcription PCR without reverse transcriptase enzyme. 
The RT control reaction was included to check for genomic DNA contamination.
Each reaction consisted of the following:
Reagent Volume
FastStart Universal SYBR Green 
master mix
5’ (forward) Primer (20 pmol/µl)
3’ (reverse) Primer (20 pmol/µl)
cDNA 
Nuclease free water
6.25 µl
0.25 µl
0.25 µl
5 ng
Upto 12.5 µl
The following thermal cycling program was used (StepOnePlus, Applied Biosystems):
Stage Step Temperature Time Cycles
Stage 1
Stage 2
Stage 3
Stage 4
Stage 5
Taq activation 94°C 2 min 1x
Denaturation 94°C 20 sec 40x
Annealing 56°C 20 sec
Extension 65°C 40 sec
65°C 1 min 1x
95°C 15 sec 1x
60°C 15 sec
95°C 15 sec
20°C 2 min 1x
3.2.3.2 TaqMan probe based real time PCR for microRNA detection
The TaqMan MicroRNA Assay (Applied Biosystems, New Jersey, USA) was used to quantify 
microRNA expression. TaqMan probes depend on the 5'-nuclease activity  of the DNA polymerase 
used for PCR to hydrolyze an oligonucleotide that is hybridized to the target amplicon. The assay 
uses looped-primer for reverse transcription PCR to specifically  detect mature microRNAs. It 
involves two steps:
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I. Reverse transcription step: In this step, cDNA is reverse transcribed from the total RNA using 
microRNA specific looped-primers.
II. Quantitative real time PCR step: In this step, PCR products are amplified from the cDNA using 
a TaqMan MGB probe. The TaqMan MGB probe contains a reporter dye (FAMTM) linked to the 
5’ end, a minor groove binder (MGB) at the 3’ end and a non fluorescent quencher at the 3’ end 
of the probe. During the PCR reaction, the DNA polymerase cleaves the probes that  are bound 
to the target resulting in the separation of the reporter dye from the quencher leading to an 
increase in fluorescence which is quantified using the comparative ∆∆Ct method.
The two steps were performed according to manufacturer’s instructions. 
Reverse transcription:
Reagent Volume
RT Buffer 1.5 µl
100mM dNTPs 0.15 µl
RNase Inhibitor 0.19 µl
Reverse transcriptase 1 µl
5x RT primer 3 µl
RNA (2ng/µl) 5 µl
Nuclease free water 4.16 µl
Incubation for 30 minutes at 16°C
Incubation for 30 minutes at 42°C
Incubation for 5 minutes at 85°C
Quantitative real time PCR:
Reagent Volume
2x TaqMan Universal PCR master 
mix II, no UNG
20x TaqMan probe
cDNA
Nuclease free water
10 µl
1 µl
1.33 µl
7.67 µl
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The following thermal cycling program was used (StepOnePlus, Applied Biosystems):
Stage Step Temperature Time Cycles
Stage 1
Stage 2
Taq activation 95°C 10 min 1x
Denaturation 95°C 15 sec 40x
Annealing/
Extension
60°C 60 sec
Extension 65°C 40 sec
3.3 DNA analysis
3.3.1 Gel electrophoresis
Agarose gel electrophoresis was used to separate DNA fragments according to their lengths. 
Electrophoresis enables the separation of the negatively  charged nucleic acid molecules through an 
agarose matrix according to their sizes. Ethidium bromide was used to visualize the separated DNA 
fragments under UV light (312 nm). 1.5% agarose gel was prepared by dissolving 1.5 g of agarose 
in 100 ml of 1x TAE buffer by boiling for 2 minutes. The solution was allowed to cool down to 
40°C before adding 10 µl of Ethidium bromide (1 mg/ml) to it. The solution was then poured into 
trays (Peqlab) and allowed to set. The tray was then placed into the electrophoresis chamber filled 
with 1x TAE. The DNA samples were mixed with 2 - 5 µl of loading buffer and allowed to run for 
45 minutes at  120 V. To distinguish the length of the DNA fragments, 1 kb and 100 bp DNA ladders 
(25 ng/µl, NEB) were run along with the samples. The gel was then visualized under UV lamp. The 
DNA fragments of the required size were extracted from the agarose gel using QIAquick Gel 
Extraction Kit (Qiagen) according to the manufacturer’s instruction.
3.3.2 Transformation of plasmid DNA into E. coli
Plasmid DNA was transformed into electrocompetent E. coli cells (DH10B). Electrocompetent 
E.coli DH10B cells were thawed on ice and 1 – 2 µl of plasmid DNA was added to 50 µl of the 
cells. The suspension was mixed, transferred into Gene Pulser 0.1 cm cuvettes (Bio-rad) and a short 
1.8 kV electromagnetic pulse was applied using the Bio-rad micropulser. The electroporated cell 
suspension was mixed with 250 µl of LB medium, transferred into an 1.5 ml microfuge tube and 
was incubated at 37°C and 350 rpm in a thermomixer (Eppendorf) for 1 hour. 50 – 150 µl of the cell 
suspension was then plated on LB plates containing the corresponding antibiotic (33 µg/µl 
Kanamycin or 100 µg/µl Ampicillin). The plates were incubated overnight.
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3.3.3 DNA sequence analysis
2 µg of plasmid DNA was diluted to a final volume of 20 µl and the primers at  a concentration of 10 
pmol/µl in a volume of 10 µl was sent to MWG Eurofins Operon for sequencing. The sequencing 
results were analyzed using the software eBIOX. In silico handling of DNA sequences for the 
cloning experiments were performed using the softwares - Gene Construction Kit (Textco), 
MacVector 12.0.6 and Serial Cloner 2.
3.3.4 Mini plasmid DNA purification
Clones were picked from LB agar plates after transformation and inoculated in 5 ml LB broth with 
the respective antibiotic. The cultures were incubated at 37°C and 180 rpm until the exponential 
growth phase (8 - 12 hours). 1.5 ml of the log phase culture was centrifuged at 13000 rpm for 2 
minutes to spin down the cells. The cell pellet was resuspended in 250 µl of buffer P1, followed by 
the addition of 250 µl of buffer P2 and 5 min incubation at RT. To this, 300 µl of neutralization 
buffer P3 was added and centrifuged at  13000 rpm and 4°C for 10 minutes. The supernatant was 
collected and plasmid DNA was precipitated by  the addition of 750 µl of isopropanol and 10 minute 
centrifugation at 13000 rpm and 4°C. The pellet was washed twice with 70% ethanol, air dried and 
suspended in 20 µl of nuclease free water. 
For maxi cultures, 100 µl of mini culture was inoculated in 100 - 200 ml LB medium with the 
corresponding antibiotic and incubated overnight at  37°C accompanied by  rigorous shaking. 
Plasmid DNA was purified from these cultures using the Maxi DNA purification kit/Endofree Maxi 
DNA purification kit (Qiagen).
3.4 Protein analysis
3.4.1 Preparation of protein lysates
Tissues (50-100 mg) were homogenized in 800 µl of protein lysis buffer protease and phosphatase 
inhibitors (Roche). In the case of adherent cells such as NRCM and NRCF, the stimulated cells 
were washed with PBS and 250 µl of cold protein lysis buffer was added to the plates. The cells 
were scraped using a cell scraper and the lysates were transferred into a 1.5 ml tube. The cell lysates 
were then sonicated. The lysates were then incubated with 1/10th volume of 5% (v/v) Benzonase at 
RT for 10 min. Benzonase is a genetically engineered endonuclease which degrades all forms of 
nucleic acids (DNA, RNA). The tubes were then placed in an ultrasonic bath at 4°C for 5 min. The 
samples were then centrifuged at 12000 rpm for 20 min at 4°C to clear the lysates and were stored 
at -80°C until use.
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3.4.2 Quantification of protein concentration
The concentration of the protein lysates was determined by the bicinchoninic acid colorimetric 
assay using the BCA protein assay  kit (Thermo Scientific). The peptide bonds in the protein reduce 
the divalent copper ions to monovalent ions, which then chelates with the bicinchoninic acid to 
form a purple coloured complex with absorption maximum at 562 nm. The absorbance of the 
samples at 562 nm was measured using an Infinite 200 spectrophotometer (Tecan). The protein 
concentration was then evaluated with reference to serial dilutions of the internal calibration 
standard bovine serum albumin.
3.4.3 Western blot
8-12% polyacrylamide gels were used for the separation of proteins of different sizes. 
Reagent Stacking gel Separating gel
8% 10% 12%
Acrylamide/
Bisacrylamide 30%/
0.8% (v/v)
Lower buffer (4X)
Upper buffer (4X)
H2O
Glycerol (80%)
TEMED
APS(10%)
0.5 ml 4 ml 4.5 ml 5 ml
- 3.8 ml 3.8 ml 3.8 ml
1.25 ml - - -
3.2 ml 4.7 ml 4.2 ml 3.7 ml
- 2.5 ml 2.5 ml 2.5 ml
6 µl 12 µl 12 µl 12 µl
48 µl 72 µl 72 µl 72 µl
The gels were cast using the Mini-PROTEAN casting stand (Biorad). The samples were denatured 
by boiling at 95°C for 5 min. The gel electrophoresis chamber was filled with 1X running buffer, 
samples were loaded into the wells and 30 mA current per gel was applied at maximum voltage. 
The separated proteins on the gel were then transferred onto a PVDF membrane (Millipore) using 
wet transfer (Mini-PROTEAN transfer system, Biorad). The PVDF membrane was cut to the size of 
the mini-gel and was activated by  immersing in methanol for 2 minutes. The membrane was then 
placed on the cassette facing the anode and the gel was placed facing the cathode side. The 
membrane and the gel were sandwiched between 1-2 layers of filter paper. The transfer was carried 
out at 385 mA current at maximum voltage for 90 min.
After the transfer process, the membrane was blocked with 5% BSA blocking buffer for 1-2 hours 
at RT on a horizontal shaker and then incubated with the following primary antibody overnight at 
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4°C: anti-KSR1 (#611576, BD Biosciences), anti-MAPK1/3 (#9102, Cell Signaling), anti-
PhosphoMAPK1/3 (#9101, Cell Signaling), anti-IGF1R (#3027, Cell Signaling), anti-GRB2 
(#3972s, Cell Signaling). A monoclonal anti-heat shock protein 90 (HSP90, sc-13119, Santa-Cruz) 
was used as a loading control. For detection of phosphoMAPK1/3, cells were stimulated for 10 min 
with 10 µM PE before lysis. After incubation, the membrane was washed three times with BSA 
washing buffer for 10 min at RT. The membranes were then incubated with the appropriate 
peroxidase-conjugated secondary  antibodies (1:10000) at RT for 90 min. The membranes were 
again washed with the BSA washing buffer.
The proteins were detected by chemiluminescence. ECL Plus (GE Healthcare) was applied to the 
membrane according to the manufacturer’s instructions. The signal was visualized using a Fujifilm 
LASmini4000 instrument (Fujifilm). The blots were then analyzed using the Multigauge software 
(Fujifilm).
3.5 Luciferase reporter assay
This assay is used to demonstrate a direct interaction of a microRNA with the 3’ UTR of its target. 
Briefly, the 3’ UTR of a target gene is cloned into the MCS located within the 3’ UTR of Firefly 
Luciferase in the reporter construct, pmiR-RL-TK2 (a gift from Prof. Gunter Meister). A direct 
interaction between the microRNA and the binding site would result in decreased Firefly Luciferase 
activity. The vector also contains a second luciferase gene (Renilla) under the control of a different 
promoter for normalization purposes. 
3.5.1 Cloning of 3’ UTR
3.5.1.1 PCR amplification of 3’ UTR
Primers were designed to amplify a 200 bp  region from the 3’ UTR of the target gene with the miR 
binding site in the middle. Restriction sites for SpeI and SacI were added to the forward and reverse 
primer respectively. To enable proper digestion a stretch of 4-8 bases was added to the 5’ end of the 
primers before the restriction sites. The inserts were amplified from human uterus genomic DNA 
for human 3’ UTR and rat cDNA for cloning the rat  3’ UTR. Accuprime Pfx polymerase was used 
for the amplification of the inserts.
32
Reagent Volume
10X Accuprime Pfx buffer
Forward primer
Reverse primer
Template DNA
Accuprime Pfx polymerase
Nuclease free water
5 µl
20 pmol
20 pmol
100 - 200 ng
2.5 units
upto 50 µl
The following thermal cycling program was used for amplification:
Stage Step Temperature Time Cycles
Stage 1
Stage 2
Stage 3
Polymerase 
activation
95°C 2 min
Denaturation 95°C 15 sec 35 cycles
Annealing/
Extension
55 - 65°C 20 sec
Extension 68°C 60 sec
Final extension 68°C 5 min
After the PCR, the PCR amplified products were run on a 1.5 % agarose gel for 45 minutes and 
visualized under UV light. The region of gel containing the amplicon was excised using a sterile 
scalpel in a microfuge tube.
3.5.1.2 Gel extraction of the insert
The amplified insert within the gel was extracted using the QIAquick gel extraction kit (Qiagen, 
Hilden). 3X volume of buffer QG was added to 1 volume of the gel and incubated at 50°C for 10 
minutes. Next, 1X volume of isopropanol was added to the sample and mixed thoroughly. The 
samples were then added to the QIAquick spin columns and centrifuged for 1 minutes. The run 
through was discarded and the spin column was washed with PE buffer followed by an additional 
dry spin to ensure the complete removal all the flow through. The inserts were then eluted by the 
addition of  nuclease free water to the spin column followed by a 1 minute centrifuge. 
3.5.1.3 Restriction digestion
The insert and the vector were then digested using with the enzymes SpeI and SacI (New England 
Biolabs), followed by incubation at 37°C for minimum 2 hours. 
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Reagent Volume
Purified insert/vector
SpeI
SacI
NEB Buffer 4
BSA(100X)
Nuclease free water
30 µl/1 µg
1 µl
2 µl
5 µl
0.5 µl
upto 50 µl
The restriction digestion products were then run on an agarose gel and the digested products were 
extracted using the QIAquick gel extraction kit. 1µl of the eluted product was again run on an 
agarose gel to estimate the relative concentration of the insert and the vector.
3.5.1.4 Ligation of the insert and vector
Overnight ligation at 16°C was performed using T4 DNA ligase (New England Biolabs). 
Reagent Volume
10X ligase buffer
Vector DNA fragment
Insert DNA fragment
T4 DNA ligase
Nuclease free water
1 µl
10 - 50 ng
5 - 250 ng
1 µl
upto 10 µl
After overnight ligation, the ligation reaction was deactivated by heating for 10 minutes at 65°C. 
3.5.1.5 Transformation of the ligation product
3µl of the ligation reaction was transformed into electrocompetent E. coli cells (DH10B) and plated 
on LB agar plates with Ampicillin. The plates were incubated at 37°C overnight and the resulting 
colonies were amplified in LB broth with ampicillin followed by  plasmid isolation. The clones were 
screened by restriction digestion with SpeI and SacI enzymes. The inserts were sequenced to 
ascertain proper cloning and the vector containing the insert was amplified using the Endofree Maxi 
kit (Qiagen).
3.5.2 Site directed mutagenesis 
The miR binding site in the insert within the reporter construct were mutated using the Quikchange 
II site directed mutagenesis kit  (Stratagene). The QuikChange II site-directed mutagenesis method 
is performed using PfuUltraTM high-fidelity (HF) DNA polymerase for mutagenic primer-directed 
34
replication of both plasmid strands. The basic procedure utilizes a supercoiled double-stranded 
DNA (dsDNA) vector with an insert of interest and two synthetic oligonucleotide primers, both 
containing the desired mutation. The oligonucleotide primers, each complementary to opposite 
strands of the vector, are extended during temperature cycling by PfuUltra HF DNA polymerase, 
without primer displacement. Extension of the oligonucleotide primers generates a mutated plasmid 
containing staggered nicks. Following temperature cycling, the product is treated with Dpn I. The 
Dpn I endonuclease is specific for methylated and hemimethylated DNA and is used to digest the 
parental DNA template and to select for mutation-containing synthesized DNA. 
3.5.2.1 Mutagenic primer design
Forward and reverse primers containing the mutated miR binding sites in the middle (25-45 bp 
long) with a melting temperature (Tm) ≥ 78°C were designed for the mutagenesis reaction.  The 
PCR reaction for the generation of the mutant strand was set up according to the following table:
Reagent Volume
10X reaction buffer
dsDNA template
Oligonucleotide primer 1
Oligonucleotide primer 2
dNTP mix
PfuUltra HF DNA polymerase
5 µl
5-50 ng
125 ng
125 ng
1 µl
1 µl
The PCR was performed according to the following parameters:
Stage Step Temperature Time Cycles
Stage 1
Stage 2
Stage 3
Polymerase 
activation
95°C 30 sec
Denaturation 95°C 30 sec 18 cycles
Annealing/
Extension
55°C 1 min
Extension 68°C 60 sec/kb of 
plasmid length
Final extension 68°C 5 min
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3.5.2.2 DpnI digestion and transformation
The PCR products were digested with 1 µl of DpnI restriction enzyme (10 U/µl) for 1 hour at 37°C. 
This reaction ensures the digestion of the parental i.e. non mutated supercoiled dsDNA. The 
digested product is then transformed into electrocompetent E. coli cells (DH10B) and plated on LB 
agar plates with Ampicillin. The plates were incubated at 37°C for minimum 16 hours and the 
resulting colonies were screened for the presence of mutated 3’ UTR by sequencing. 
3.5.3 Measuring luciferase activity
The luciferase reporter assay is performed on NRCMs transfected with the reporter constructs 
containing the native and mutated 3’ UTR sites along with miR mimics/antimirs.
3.5.3.1 Transfection
0.1-0.12 million NRCMs per well were seeded onto a 96 well plate for the assay. After 24 hours, the 
NRCMs were transfected simultaneously  with 150 ng of native/mutated reporter construct  and miR 
mimic/antimiR (12.5 - 25 nM). Luciferase activity was then measured after 24 hours using the Dual 
luciferase reporter assay kit (Promega).
3.5.3.2 Luciferase assay
The cells were washed with 1X PBS followed by the addition of 20 µl 1X passive lysis buffer. The 
plate was gently rocked on a shaker at RT for 15 - 30 minutes to ensure cell lysis. Homogenous cell 
lysates were obtained by manually scraping the wells. 50µl of LARII reagent (luciferase substrate) 
was added to each well and the firefly luminescence was measured immediately in Infinite 200 
spectrophotometer (Tecan). To measure renilla luciferase activity, the luminescence reaction was 
stopped by the addition of 50 µl Stop  and Glo reagent, followed by  the measurement of 
luminescence. The firefly luciferase activity was normalized to the renilla luciferase activity.
3.6 Generation of adenoviral shRNA constructs
3.6.1 Cloning of shRNA entry vector
An shRNA entry vector for the overexpression of shRNA of interest was generated using the 
BLOCK-iT RNAi kit (Life Technologies). The kit facilitates the generation of a vector to express 
short hairpin RNA (shRNA) for use in RNA interference (RNAi) analysis of a target gene in 
mammalian cells. The double stranded oligo encoding the shRNA of interest was cloned in the 
pENTR/U6 vector as shown in Fig 6. The presence of human U6 promoter, which is recognized by 
Polymerase III, helps in highly  sustained expression of the shRNA molecules. The shRNA molecule 
that is expressed from the U6 RNAi cassette leads to the formation of an intramolecular stem-loop 
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structure similar to the structure of a miRNA. This hairpin is then processed by the endogenous 
Dicer enzyme into a 21-23 nt siRNA duplex. 
Two single-stranded DNA oligonucleotides; one encoding the target shRNA (“top  strand” oligo) 
and the other its complement (“bottom strand” oligo) were designed using the Life Technologies’ 
RNAi Designer, an online tool. The top and bottom strand oligos were then annealed to generate a 
double stranded oligo suitable for cloning into the pENTR/U6 vector. A sequence of 4 nucleotides 
CACC was added to the 5’ end of the top strand to enable directional cloning and similarly AAAA 
was added to the 5’ end of the bottom strand oligo. As per the instructions of the kit, the shRNA 
sequence was initiated with a G residue since the transcription if the native U6 snRNA initiated at 
G. If G was part of the target sequence then a complementary  C was added to the 3’ end of the top 
strand oligo. The top and bottom strands were synthesized by MWG Eurofins. The two oligos were 
annealed according to the following table:
Reagent Volume
Top strand oligo (200µM)
Bottom strand oligo (200µM)
10X annealing buffer
Oligonucleotide primer 2
Nuclease free water
5 µl
5 µl
2 µl
125 ng
8 µl
The reaction was incubated at 95°C for 4 minutes and then left to cool down at RT for 10 minutes. 
After the annealing reaction the final concentration of the double stranded oligo was 50 µM. This 
was then serially diluted. First dilution: 1µl of 50 µM  ds oligo was diluted with 99 µl of nuclease 
free water. Second dilution: 1 µl of the first dilution was mixed in 89µl of nuclease free water along 
with 10 µl of 10X annealing buffer. The dilutions were stored at -20°C until further use. 
The double stranded oligos was then ligated to the pENTR/U6 vector using T4 DNA ligase with a 
10:1 molar ratio of ds oligo insert:vector for ligation as previously described. The ligated vector 
was then transformed into electrocompetent E. coli cells (DH10B) and plated on LB agar plates 
with Kanamycin.
37
Fig 6: Flowchart depicting the generation of the shRNA entry clone (Illustration from the BLOCK-iT 
RNAi manual - Invitrogen)
3.6.2 Generation of the shRNA destination vector
The entry vector was then used to generate the destination vector (pAD/CMV vector) by means of a 
Gateway  LR recombination reaction for the generation of adenovirus overexpressing the shRNA. 
The pENTR/U6 shRNA entry vector possesses attL sites, which can be recombined with a 
destination vector containing attR sites. The LR Clonase II (Life technologies) enzyme mix 
contains bacteriophage lambda recombinant Integrase and Excisionase, and E.coli- encoded protein, 
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Experimental Outline 
 
Flow Chart The figure below illustrates the major steps necessary to produce a pENTR™/U6 
entry clone using the BLOCK-iT™ U6 Entry Vector Kit. 
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Integration Host Factor, facilitating the in vitro recombination reaction. The recombination reaction 
was set up according to the following table:
Reagent Volume
Entry clone (pENTR/U6 shRNA)
Destination vector (pAD/CMV)
LR Clonase II
TE buffer pH 8.0
15 - 150 ng
150 ng
2 µl
upto 10 µl
The recombination reaction was carried out at 25°C for 5 hours after which it was inactivated by the 
addition of 1µl Proteinase K followed by a 10 minute incubation at 37°C. After the recombination, 
1 µl of the recombined destination vector (pAD/CMV shRNA) was transformed into 
electrocompetent E. coli cells (DH10B) and plated on LB agar plates with Ampicillin. Positive 
clones were confirmed by sequencing followed by Endofree purification using the Endofree Maxi 
kit (Qiagen). 
3.6.3 Generation of adenoviruses
6 µg of Endofree purified pAd/CMV shRNA destination vector was digested with PacI restriction 
enzyme and incubated for 2 hours at 37°C. The digested plasmid was precipitated with Ethanol and 
0.1 volume of 3M sodium acetate followed by  3 volumes of 100% Ethanol and precipitation at 
-80°C. The DNA was then pelleted by centrifugation at 4°C, which was followed by a washing step 
with 70% Ethanol. The pellet was finally suspended in nuclease free water. 2 µg of the plasmid 
DNA was transfected into HEK293 cells using the transfecting agent Effectene (Qiagen). The DNA 
was mixed with buffer EC to a total volume of 150 µl and the samples were incubated at RT for 5 
min with 16 µl of enhancer. The samples were then incubated at RT for 10 min with 25 µl of 
Effectene reagent to allow complex formation. The transfection complexes were mixed with 1 ml of 
growth medium and were added onto a 6 cm dish containing 80% confluent HEK cells in 2 ml of 
medium. The cells were incubated in a humidified 37°C/5% CO2 incubator until 80% of the cells 
were cytopathic.
For the first virus amplification, the cell suspension was centrifuged at 850 g at 4°C for 10 min 
followed by resuspension of the pellet in 1 ml of 10 mM Tris (pH 8). The suspension was subjected 
to freeze-thaw cycle twice by freezing it in liquid nitrogen and thawing in a water bath at 37°C. 
This was centrifuged again at 850 g for 10 min at  4°C to get rid of the cell debris following, which 
the supernatant was stored at -80°C.
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For the second amplification, 500 µl of the viral particle from the first amplification was added to a 
10 cm dish containing 90% confluent HEK cells. The cells were incubated in a 37°C/5% CO2 
incubator until 80 - 90% of the cells were rounded up and floating. The cells were pelleted as above 
and the cell pellet was resuspended in 2 ml of 10 mM  Tris (pH 8). The freeze-thaw cycles were 
repeated and the virus was stored at -80°C.
The third amplification process was performed similar to the second amplification process. 15 cm 
plates with 90% confluent HEK cells were used for this process. The adenovirus containing cells 
were harvested 2 days post infection. The cells were pelleted as above and the cell pellet was 
resuspended in 3 ml of 10 mM  Tris (pH 8). The freeze-thaw cycles were repeated 3 times and the 
virus was stored at -80°C.
3.6.4 Adenoviral purification and titration
The adenoviruses produced were purified and concentrated using the Adeno-X purification kit 
(Clontech, France). HEK293 cells were diluted to a concentration of 1.83 x 106 cells/ml in a total 
volume of 40 ml. The virus was mixed with the cells, seeded onto five 15 mm cell culture dishes 
and were cultured in 37°C/5%CO2 incubator until the cytopathic effect was observed (3 – 5 days). 
The cells were harvested by  centrifuging at  1500 rpm for 10 min and the pellet was resuspended in 
fresh medium. The cell suspension was then subjected to freeze-thaw cycle thrice to lyse the cells. 
After centrifugation, the supernatant was incubated with 5 µl of Benzonase at 37°C for 30 min. 
Equal volume of 1X dilution buffer was added to the lysate and was passed through an 0.45 µm 
syringe pre-filter. The adenovirus loaded into the equilibrated filter assembly  was allowed to pass 
through the filter at a flow rate of 3 ml/min. After the wash buffer was passed through the filter, the 
virus was collected in a sterile tube by  passing 3 ml of elution buffer through it. The purified virus 
was then stored at -80°C.
The Adeno-X rapid titer kit (Clontech) was used to titer the produced adenoviruses. HEK cells were 
infected with serial dilutions of the viral particles for 48 hours. Then, the cells were fixed with ice-
cold methanol and incubated with an anti-hexon antibody  (1:1000 diluted in 1% BSA/1X PBS) 
followed by incubation with HRP-conjugated anti-rat antibody  (1:500 diluted in 1% BSA/1X PBS). 
Subsequent exposure of the plate to DAB substrate solution (1:10 diluted in 1X stable peroxidase 
buffer) caused the infected cells to become brown. The infected cells (brown or black cells) were 
then counted using an inverted microscope with 20X objective in a minimum of 3 fields per 
dilution. The virus titer was then determined using the below formula:
Virus titer = (Infected cells per field) * (Fields per well) / (Volume if virus) * (Dilution factor)
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3.7 Functional assays
3.7.1 Hypertrophy assay
3.7.1.1 Immunostaining
For the hypertrophy assay, 50,000 NRCMs per well were seeded into 96-well IBIDI plates in MEM 
containing 5% FCS for 24 hours. The next day the cells were transfected with respective mimics/
antimirs and were incubated for a further 24 hours in 5% FCS. The medium was then changed to 
MEM containing 0.1% FCS and after 24 hours, were stimulated with 50 µM  phenylephrine (PE) in 
MEM containing 0.1% FCS for 48 hours. Unstimulated control cells were incubated in MEM 
containing 0.1% FCS. The cells were fixed with 100 µl 4% PFA for 5 min at RT. To remove the 
excess PFA, the cells were washed thrice with 200 µl of PBS and were permeabilised with 100 µl of 
0.2% TritonX. The plate was then incubated with 100 µl of mouse α-actinin (1:1000 diluted in PBS) 
in a humidified chamber at 37°C for 30 min. After washing with PBS, the plate was incubated with 
Alexa488-conjugated goat anti-mouse IgG (1:200 diluted in PBS) and DAPI (1:100 diluted in PBS) 
for 30 min. The cells were washed three times with PBS and 150 µl of 50% glycerol was added to 
the plate. The plate was covered using an aluminium seal cap. The cardiomyocyte area, as 
visualised by the α-actinin staining, was analysed using automated microscopy.
3.7.1.2 Automated cell-size determination microscopy
The cell size of the cardiomyocytes was determined by automated microscopy and image 
segmentation. Images were acquired automatically using a 10X objective on an AxioObserver.Z1 
(Zeiss), a motorized scanning stage (Märzhäuser), Lumen200 fluorescence illumination system 
(Prior) and Retiga4000 CCD fluorescence camera (QImaging). Metamorph imaging software 
(Molecular Devices) was used to drive the microscope automatically and for subsequent analysis of 
the acquired images. A macro function journal consisting of three subjournals was created. The first 
subjournal drove the positional scanning of the plate, focusing and image acquisition (4 images per 
well) in two different fluorescent channels – DAPI and green fluorescence (488 nm). The second 
journal created separate montage stacks of the images acquired at the two fluorescent intensities and 
also an overlay  montage stack by merging the 2 images together. The third subjournal determined 
the cell size and number, as indicated by  the α-actinin staining for cardiomyocyte area and nuclei 
staining with DAPI, using the cell scoring plug-in of the software.
3.7.2 TUNEL assay
Cleavage of genomic DNA during apoptosis may  yield double stranded, low molecular weight 
DNA fragments (mono- and oligo-nucleosomes) as well as single strand breaks (“nicks”) in high 
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molecular weight DNA. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) is 
a method for detecting DNA fragmentation by labeling the terminal end of nucleic acids. This assay 
was performed using the In situ cell death detection kit, Fluorescein (Roche). The assay involved 
two stages namely, Stage 1: Labeling of DNA strand breaks, by Terminal deoxynucleotidyl 
transferase (TdT), which catalyzes polymerization of labeled nucleotides to free 3’-OH DNA ends 
in a template independent manner (TUNEL-reaction). Stage 2: Fluorescein labels incorporated in 
nucleotide polymers are detected and quantified by fluorescence microscopy. The assay was 
performed either with transfected NRCM plated on 12 mm coverslips or on paraffin embedded 
cardiac tissue. 
3.7.2.1 Isolated NRCMs
For NRCMs, 12mm coverslips were placed in a 12 well plate and coated with Poly-D-Lysine for 1 
hour in dark. The wells and coverslips were then gently  washed with 1X PBS. 0.4 million NRCM 
were seeded onto the 12 well plate containing the coverslips. After 24 hours, the NRCM were 
transfected with mimics/antimirs as described in the section 3.1.2. After 72 hours of transfection the 
NRCMs were washed with 1X PBS and fixed with 500µl of 4% PFA for 5 minutes. The cells were 
washed three times with 1X PBS following which, the TUNEL reactions were performed. The cells 
were permeablized with 0.2% Triton-X for 2 minutes at room temperature. Then, they were washed 
thrice with 1X PBS. The TUNEL reaction mix was prepared by mixing 5 µl of vial 1 (Enzyme) and 
45 µl of vial 2 (labeling solution). 25 µl of the reaction mix was added to the coverslips with cells 
and placed on slides. These slides were incubated in for 1 hour at 37°C in dark in a humidified 
chamber. As a negative control, only  the labeling solution without the enzyme was added to the 
cells. As a positive control, the cells were incubated with DNase I for 10 minutes at RT followed by 
the addition of the TUNEL reaction mix. After the incubation the cells were gently rinsed three 
times with 1X PBS and mounted on a slide with Vectashield fluorescence mounting medium 
containing DAPI. The slides were microscopically analyzed and 20X images were acquired under 
DAPI and green fluorescence (488 nm) channels using Metamorph imaging software (Molecular 
Devices). The two images were overlaid and the percentage of apoptotic cells were calculated.
3.7.2.2 Paraffin embedded cardiac tissue
For paraffin embedded tissue sections, the slides containing the sections were first dewaxed and 
rehydrated by immersing the slides in 100% Toluol (2 times, 10 minutes each), followed by 100% 
Ethanol (twice, 5 minutes each), 90% Ethanol (5 minutes), 70% Ethanol (5 minutes), 50% Ethanol 
(5 minutes) and finally 1X PBS (5 minutes). The sections were then permeablized with Proteinase 
K (20 µg/ml in 10 mM  TrisCl, 7.4-8 pH) for 15 minutes at 37°C. This was followed by  washing the 
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sections in 1X PBS (three times, 5 minutes each). The sections were covered with the TUNEL 
reaction mix containing the enzyme and labeling mixture and incubated for 1 hour at 37°C in a 
humidified chamber in dark. After incubation, the sections were washed again with 1X PBS (three 
times, 5 minutes each). The sections were then mounted with Vectashield fluorescence mounting 
medium containing DAPI, covered with coverslip and sealed using nail polish. The slides were 
microscopically  analyzed and 10X images were acquired under DAPI and green fluorescence (488 
nm) channels using Metamorph imaging software (Molecular Devices). The two images were 
overlaid and the percentage of apoptotic cells was calculated.
3.7.3 RNAi knockdown assay
3.7.3.1 RNAi with shRNA
For shRNA knockdown experiments, hypertrophy  assay  was performed with adenoviruses encoding 
shRNA against Mapk1 and an shRNA control. 50,000 NRCMs per well were first seeded on to 
optically optimized 96 well plates and cultured for 24 hours in 5% FCS containing MEM medium 
at 37°C and 1% CO2. The cells were then infected with Adeno-shMapk1 and Adeno-shctrl. The 
medium was changed the next day and transfection with 50 nM Antimirs was performed according 
to the method described before. After 48 hours, the cells were stimulated with PE to induce 
hypertrophy. After two days, immunostaining and automated cell size measurements were 
performed.
3.7.3.2 RNAi with siRNA
For siRNA knockdown experiments, hypertrophy assay was performed with siRNAs targeting the 
four miR-378 targets, i.e. si-Mapk1, si-Grb2, si-Ksr1 and si-Igf1r. 50,000 NRCMs per well were 
seeded on to optically optimized 96 well plates and cultured for 24 hours in 5% FCS containing 
MEM medium at 37°C and 1% CO2. The next the cells were transfected with 100 nM siRNA and/or 
50 nM antimiR along with the respective controls as described before. After 48 hours, the cells were 
stimulated with PE to induce hypertrophy. After two days, immunostaining and automated cell size 
measurements were performed.
3.8 Animal experiments
3.8.1 β1-adrenergic receptor transgenic mice
β1-transgenic was used as one of the heart failure models in the study. The mice were generated by 
overexpression of ß1-adrenergic receptor under the control of cardiomyocyte specific α-MHC 
promoter93. The transgenic mouse line TG4 that had 15-fold increase in its receptor numbers than 
the wild type litter mates was used in the study. These mice had high cardiac contractility at young 
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age but developed progressive heart failure with myocyte hypertrophy, decreased contractility and 
reduced cardiac function at 9 months of age.
3.8.2 Pressure overload induced hypertrophy
Pressure overload hypertrophy  was induced by thoracic aortic constriction (TAC) performed on 8 
weeks old male C57BL/6N mice (Charles River Laboratories). Briefly, animals were anesthetized 
with isoflurane (2%) and, after opening the chest, the aorta was ligated with a 6-0 nylon fibre 
around a 27G cannula. In sham surgery, only  the chest was opened, but no ligation of the aorta was 
carried out. Cardiac dimensions and function were analyzed by pulse–wave Doppler 
echocardiography essentially before TAC/sham surgery and before sacrificing the animals. 
3.8.3 Generation of AAV vectors
Recombinant AAV-miR-378 and AAV-GFP vectors used in this study were prepared by the AAV 
Vector Unit at the International Centre for Genetic Engineering and Biotechnology  Trieste94. 
Briefly, infectious recombinant AAV vector particles were generated in HEK293T cells by a cross-
packaging approach whereby  the vector genome was packaged into AAV capsid serotype-995. Viral 
stocks were obtained by CsCl2 gradient centrifugation; rAAV titers, determined by measuring the 
copy number of viral genomes in pooled, dialyzed gradient fractions96 were in the range of 1x1012 
to 1x1013 genome copies per milliliter. For the AAV-miR-378 preparation, the genomic pre-miR 
sequence was sub-cloned into the vector plasmid derived from pAAV-MCS (Agilent Technologies) 
containing a modification in the multiple cloning site to match the insert ends. In all the vectors 
used in this study, the transgene is expressed under the transcriptional control of the CMV 
immediate early  promoter. The AAVs were injected into the tail vein of 5 week old male C57BL/6N 
mice (Charles River Laboratories).
3.8.4 Echocardiographic analysis
Vevo 700 was used for echocardiographic measurements (Visual Sonics). Mice were subjected to 
anesthesia by inhalation (2% isoflurane/98% O2) and were fixed on a hot  plate maintained at 37°C. 
Isoflurane concentration was adjusted such that the heartbeat was in the range of 450±50 beats per 
min. The chest was shaved and ‘Aquasonic’ ultrasound transmission gel (Parker laboratories, New 
Jersey) was applied. The ultrasonic probe in the long axis (B-mode) was placed on parasternal line 
and the left  ventricle, and the position was determined. The echocardiogram was then recorded in 
the short axis mode (M-mode) by rotating the transducer by 90°C. Left ventricular internal diameter 
(LVID), left ventricular posterior wall thickness (LVPW) and intraventricular septal thickness (IVS) 
was determined under both systolic (s) and diastolic (d) phases. The cardiac function parameters 
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such as ejection fraction (EF) and fractional shortening (FS) were calculated using the following 
formulae:
FS % = (LVIDd - LVIDs)/LVIDd * 100
EF % = (LVd - LVs)/LVd * 100
3.8.5 Histochemical and immunohistochemical analysis
3.8.5.1 Sirius red and fast green staining
For the analysis of collagen deposition, paraffin sections of the myocardium were stained with 
Sirius red and Fast green. The slides containing the sections were first dewaxed and rehydrated by 
immersing the slides in 100% Toluol (2 times, 10 minutes each), followed by 100% Ethanol (twice, 
5 minutes each), 90% Ethanol (5 minutes), 70% Ethanol (5 minutes), 50% Ethanol (5 minutes) and 
finally double distilled water (5 minutes). The slides were treated with preheated Bouin’s solution at 
55°C for 1 hour. The slides were then washed under running water for 10 minutes. This was 
followed by  the addition of 0.1% Fast green for 10 minutes at RT. The slides were then rinsed in 1% 
acetic acid for 2 minutes and running water for 5 minutes. The sections were stained with the Sirius 
red solution for 30 minutes followed by a brief 10 second wash with double distilled water. This 
was followed by dehydration of the sections by immersing the slides in 70% Ethanol for 10 
seconds, followed by 100% Ethanol for 1 minute and finally  100% Toluol for 3 minutes. The slides 
were mounted with DEPEX, a synthetic mounting medium and covered with a coverslip. The slides 
were analyzed and images under 10X magnification were obtained. Sirius red staining was 
measured in an automated manner using Metamorph imaging software (Molecular Devices). 
Collagen content was calculated as the percentage of the area in each section that  was stained with 
Sirius red. 
3.8.5.2 WGA staining
For analysis of cardiomyocyte hypertrophy, myocardium tissue sections (6 µm) were stained with 
SYTOX Green (Life Technologies) - for staining of cell nuclei and ALEXA 647 labelled wheat-
germ agglutinin (WGA, Invitrogen) - for determination of myocyte cross sectional areas. The slides 
containing the sections were first  dewaxed and rehydrated by  immersing the slides in 100% Toluol 
(2 times, 10 minutes each), followed by 100% Ethanol (twice, 5 minutes each), 90% Ethanol (5 
minutes), 70% Ethanol (5 minutes), 50% Ethanol (5 minutes) and finally 1X PBS (3 times, 5 
minutes each). The sections were stained with ALEXA 647 labelled WGA (1:500, diluted with 1X 
PBS) and nuclear stain SYTOX green (1:500) and incubated for 1 hour at RT. After incubation, the 
slides were washed 3 times with 1X PBS. The slides were mounted with Vectashield fluorescence 
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mounting medium and covered with a coverslip. The sections were then analyzed under the 
microscope and images were acquired. Confocal images were taken at 20x magnification at areas of 
transversely cut muscle fibers. Individual cells were analyzed in an automated manner. Common 
morphology  filters were used in the MetaMorph software (Molecular Devices) to draw lines 
separating individual cells based on the WGA staining. Thresholding was applied to exclude regions 
of background (no cells) or extensive fibrosis. Nuclei were extracted from the green channel. Using 
morphology  filters nuclei that were touching any cell borders were automatically excluded. The 
remaining nuclei were used to select for cardiomyocytes with centralized nuclei. Cells with a width 
of less than 7 µm or an area of less than 50 µm were considered non-myocytes and excluded from 
the analysis. Averages for area and breadth (width of the object perpendicular to the longest chord) 
of analyzed cells (>20 cells per section) were exported using the MetaMorph integrated 
morphometry analysis function.
3.9 Statistical analysis
Data are shown as mean±SEM. Statistical analysis was performed with Prism (GraphPad Software). 
The Student  t test  or 2-way ANOVA followed by  the Bonferroni test was used as appropriate. Data 
were analyzed for normality  using Shapiro-Wilk or Kolmogorov-Smirnov test. Testing for common 
variance was carried out using F test. If necessary, Box-Cox transformation was used to meet the 
requirement of normality and equal variances before comparing means.
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4 RESULTS**
4.1 Screening of potential microRNAs
To identify candidate microRNAs, two strategies were simultaneously employed. The first was to 
screen for miRs that could potentially  regulate cardiomyocyte hypertrophy  and the second was to 
screen for miRs based on their expression and regulation in the failing heart. 
Libraries of multiple synthetic microRNAs were screened to identify  hypertrophy regulating 
microRNAs97. The screen employed automated microscopy and an edge detection algorithm to 
assess cardiomyocyte size. Results of the screen showed several microRNAs with prohypertrophic 
and antihypertrophic effects on myocyte size. Of these, miR-378 was found to negatively regulate 
hypertrophy. Interestingly, miR-378 also appeared as one of the candidates in global expression 
profiling studies performed in the lab98. The results of the expression profiling study were analyzed 
according to the following criteria:
I. Expression strength in the heart
II. Deregulation in the failing mouse heart
III. Enrichment in isolated cardiomyocytes compared to cardiac fibroblasts.
Expression profiling results from early and late stages of heart failure showed several deregulated 
microRNAs. Of these microRNAs, miR-378 emerged as a potentially  interesting microRNA that 
was highly  expressed in the mouse heart and downregulated in the failing heart. Also, expression 
profiling from isolated adult mouse cardiomyocytes and adult cardiac fibroblasts showed that 
miR-378 was highly enriched in cardiomyocytes compared to cardiac fibroblasts.
4.2 MiR-378 expression
4.2.1 MiR-378 expression in mice
MiR-378 is a muscle enriched microRNA. qPCR analysis in lung, heart and skeletal muscle showed 
the highest enrichment in skeletal muscle followed by heart (Fig 7A). An analysis of the microRNA 
levels from the embryonic stages showed reduced miR-378 levels that increased after birth 
suggesting that the expression of the microRNA undergoes a boost during mouse ontogenesis (Fig 
7B).
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** This section (including the figures) was published in Ganesan et al.Circulation 2013 (169) 
4.2.2 MiR-378 expression in cardiomyocytes
The two major cell types in the myocardium are cardiomyocytes and cardiac fibroblasts. An 
analysis of miR-378 levels in these two cell types showed a 10fold enrichment of the microRNA 
levels in cardiomyocytes (Fig 7C). 
4.2.3 MiR-378 expression in the failing heart
Failing myocardium shows an activation of the fetal gene program99. Two different heart failure 
models were analyzed to determine the regulation of miR-378: first, a β1-adrenergic receptor-
transgenic mouse model, which leads to severe heart failure93 and second, a transthoracic aortic 
constriction (TAC) model for chronic pressure overload. Both mice models showed a significant 
decrease of miR-378 levels by 54% and 42% respectively (Fig 7D).
In line with the mouse models of heart failure, human failing myocardium showed a similar pattern 
of miR-378 downregulation. Human heart biopsies from dilated cardiomyopathy patients showed a 
significant decrease in miR-378 expression levels (Fig 7E) suggesting a prominent role for this 
microRNA in the progression of heart failure.
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Fig 7: miR-378 expression (A) qPCR analysis of miR-378 expression in various tissues (n=4). (B) 
Myocardial expression of miR-378 during development  and after birth: Levels of miR-378 were determined 
by quantitative real-time PCR in RNA prepared from myocardial tissue obtained at the age indicated. (n=1 
for E15.5, E16.5, E17.5, E18.5; n=4 for D1, D2, D30, D120) (C) miR-378 expression determined by qPCR 
in neonatal rat cardiomyocytes compared to cardiac fibroblasts (n=3 independent cell isolations). (C) 
Myocardial miR-378 expression in cardiac disease determined by qPCR. (Left) Quantitation of miR-378 in 
left  ventricular myocardium from a murine heart failure model (β1-adrenergic receptor-transgenic mice or 
wild-type litter mates) and from transthoracic aortic constriction (TAC) or sham-operated controls (n=5). (D) 
Quantitation of miR-378 in human heart biopsies from patients with dilated cardiomyopathy (n=12) or non 
failing control biopsies (n=5). (D) Experimental error is shown as SEM, statistical significance is shown as p 
< 0.05 (*), p < 0.01 (**), p < 0.001 (***) or n.s. (non-significant). 
4.3 Manipulation of miR-378 expression in NRCM
4.3.1 miR-378 inhibits cardiomyocyte hypertrophy
Synthetic miR-378 mimic and a miR-control (miR-ctrl) were transfected into NRCM under basal 
and phenylephrine (PE)-stimulated conditions and the resulting affect on cardiomyocyte size was 
measured. The transfection of miR-378 had only  a marginal affect under basal conditions but 
largely prevented PE-induced cardiomyocyte hypertrophy  (Fig 8A). PE treatment resulted in an 
increase in the expression of hypertrophic markers like Nppa and Nppb. miR-378 transfection led to 
a significant decrease in the levels of both Nppa and Nppb under PE-stimulated conditions (Fig 8B). 
A reciprocal affect on the myocyte size was observed when the endogenous miR-378 was knocked 
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down using an antimiR-378. Transfection of antimiR-378 led to an increase in myocyte size under 
both basal as well as PE stimulated conditions (Fig 8C).
Fig 8 miR-378 inhibits phenylephrine (PE)-induced hypertrophy of NRCM (A) NRCM were transfected 
with miR-378 or a control molecule (miR-ctrl) followed by PE stimulation. (Left) Processed microscopic 
images of immunofluorescent staining of cardiomyocytes with an antibody against  alpha-actinin (green 
cells). Non-myocyte nuclei are automatically detected and marked in red. Scale bar = 100 µm50. (B) qPCR 
analysis of atrial natriuretic peptide (Nppa) and brain natriuretic peptide (Nppb) as markers of hypertrophy. 
Shown are the expression levels upon miR-378 transfection of PE-stimulated NRCM relative to cells 
transfected with miR-ctrl (dotted line). Graph shows results from 4 independent experiments. (C) 
Transfection of an antagonist  against miR-378, antimiR-378. Experimental conditions were analogous to 
(A). Bar graphs in (A) and (C) show results from five independent experiments performed in triplicate.
4.3.1 MiR-378 increases apoptosis in NRCM
Consistent with a previous report84, transfection of synthetic miR-378 into NRCM  lead to increased 
apoptosis under both basal and PE stimulated conditions (Fig 9A). In addition, knockdown of 
endogenous miR-378 using antimiR-378 increased cell densities under both basal as well as PE-
stimulated conditions (Fig 9B). 
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Fig 9 miR-378 increases apoptosis in NRCM (A) Apoptosis was analyzed in isolated NRCM by terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL). Representative pictures of TUNEL staining, 
96 hours after transfection with synthetic miR-378 or a scrambled sequence (miR-ctrl). The quantification 
shows results from 3 independent experiments performed in duplicate. Arrows indicate apoptotic cell nuclei, 
scale bar = 50 µm. (B) Inhibition of endogenous miR-378 reduces apoptosis in NRCM. Experiments as in 
(A), except  that antimiR-378 or antimiR-ctrl were transfected. Results are from three independent 
experiments performed in duplicate.
4.4 Screening of potential miR-378 targets
4.4.1 Selection of potential miR-378 targets
Bioinformatic target prediction tools were employed to identify  targets with conserved miR-378 
binding sites. TargetScanHuman100 (v6.2) predicted 191 conserved targets of miR-378 with a total 
of 195 conserved sites and 67 poorly  conserved sites. Functional association of miRs with signaling 
pathways was investigated using a recently  developed bioinformatic tool miTALOS101. The results 
showed the highest enrichment of targets within the mitogen-activated kinase (MAPK) signaling 
pathway. Based on evolutionary conservation and pathway analysis, four targets with miR-378 
binding sites were chosen. The four targets, mitogen-activated kinase 1 (MAPK1, also termed 
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ERK2), kinase suppressor of ras 1 (KSR1), growth factor receptor bound protein 2 (GRB2), and the 
receptor for insulin-like growth factor 1 (IGF1R) are key components of the MAPK signaling 
cascade. To screen for potential miR-378 targets, a global mRNA expression profiling study  was 
performed in NRCM transfected with synthetic miR-378 mimic and stimulated with PE. The results 
(Fig 10A) showed a downregulation of Grb2 and Ksr1 mRNA levels upon miR-378 transfection. 
The mRNA levels of Igf1r and Mapk1 were unaltered. 
4.4.2 Regulation of miR-378 targets 
To assess the regulation of the targets on the mRNA level quantitative real time PCR (qPCR) was 
performed on RNA isolated from synthetic miR-378 mimic-transfected NRCM. mRNAs of all four 
targets were found to be downregulated (Fig 10B). Next, the regulation of these targets on the 
protein level was assessed using immunoblot detection in NRCM transfected with synthetic 
miR-378 mimic. The quantification confirmed reduced protein levels of GRB2, IGF1R, KSR1 and 
MAPK1 (Fig 10C). A reciprocal increase in protein expression was observed in NRCM  transfected 
with antimiR-378. Since all four targets belong to the MAPK signaling cascade, the activation of 
MAPK1 and MAPK3 was assessed by  probing the immunoblots with antibodies against 
phosphorylated MAPK1 and MAPK3. Significant reduction in MAPK1 and MAPK3 activation 
with miR-378 and a corresponding increase in the MAPK activation with antimiR-378 transfection 
was observed.
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Fig 10 miR-378 targets several key components of the  MAPK1 pathway. (A) Microarray analysis of the 
80 most abundant mRNAs in cardiomyocytes and their alteration after miR-378 transfection. The diagram 
plots data in log2 scale from NRCM that were transfected with miR-378 or miR-ctrl and subsequently 
treated with PE. The dotted line marks theoretical values for unaltered expression in the presence or absence 
of miR-378. Bioinformatic analysis using miTALOS predicted the MAPK signaling pathway as the single 
most enriched signaling pathway, members of which are marked in red. (B) Validation of microarray data by 
quantitative PCR. NRCM were transfected with miR-378. Data show cycle threshold values for mRNAs of 
interest relative to β-actin. All data retrieved from 5 independent experiments. (C) MiR-transfected NRCM 
as in (B) were lysed and analyzed on Western blots with antibodies against  the proteins of interest, including 
activated MAPKs (p-MAPK1/3); detection of HSP90 served as a loading control. (Left) Representative 
Western blots. (Right) Quantitative analysis of Western blot data. A dotted line in the graph denotes the 
signal intensity obtained in NRCM transfected with miR-ctrl or antimiR-ctrl and to which the other data 
were normalized. Data are from two to eight independent cell isolations with two to three replicates each. 
Statistical significance was evaluated with Student’s t-test comparing the two treatments to their respective 
controls.
4.4.3 Direct interaction of miR-378 with the 3’ UTR of the four targets
To assess direct binding of miR-378 to the 3’ UTR of the four targets, luciferase reporter constructs 
with native 3’ UTR of each of the targets were generated (Fig 11A-D). Reduced firefly luciferase 
activity was observed in NRCMs transfected simultaneously with the reporter constructs and 
synthetic miR-378 mimics. NRCMs transfected with antimiR-378 showed an increase in the firefly 
luciferase activity. To test the specificity of this interaction the miR-378 binding sites in the reporter 
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constructs were mutated and the luciferase activity was measured again. Simultaneous transfection 
of the mutated constructs with either the synthetic miR-378 or antimiR-378 did not alter luciferase 
activity.
Fig 11 miR-378 interacts directly with the  MAPK-pathway factors (A)-(D) Luciferase activity of reporter 
constructs carrying luciferase cDNA and parts of the 3’UTR of target  mRNAs. (Left panels) Localization of 
binding sites for human miR-378 (hsa-miR-378) in the 3’UTR of target  mRNAs and their evolutionary 
conservation. miR-378 seed pairing in the target  regions is shaded in green. (Right panels) Quantitative 
analysis of 3’UTR luciferase activities. NRCM were transfected with miR-378 or antimiR-378 (with miR-
ctrl and antimiR-ctrl) along with reporter constructs with native 3’ UTR or mutated 3’ UTR. The dotted line 
denotes the signal intensity obtained in controls, to which other data were normalized. Data are from three 
independent experiments performed in triplicate.
4.5 Functional relevance of miR-378 targets
To assess the relevance of target inhibition in the repression of cardiomyocyte hypertrophy by 
miR-378, a strategy utilizing the opposing phenotypic effects of miR-378 and antimiR-378 on 
cardiomyocyte cell size was designed (Fig 12A). First, miR-378 induced repression of the target 
protein(s) resulted in reduced myocyte size. In addition, when endogenous miR-378 was knocked 
down using an antimiR-378, the resulting derepression of the target protein(s) resulted in increased 
myocyte size. If the targets are functionally relevant in this scenario then interference with their 
expression (e.g. by short hairpin RNA or short interfering RNA) should specifically counteract 
antimiR-378-induced hypertrophy. 
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4.5.1 Inhibition of MAPK1 derepression using a short hairpin RNA
The strategy given in Fig 12A was first  tested for Mapk1. An adenovirus was used to deliver a short 
hairpin RNA against  Mapk1 (sh-Mapk1) in NRCM  along with a scrambled control (sh-ctrl). The sh-
Mapk1 efficiently silenced MAPK1 expression while having no effect on MAPK3 (Fig 12C, upper 
right) and inhibited the antimiR-378 induced hypertrophy under PE stimulation (Fig 12B-C). 
AntimiR-378 induced an increase in NRCM  size with sh-ctrl, which was inhibited by sh-Mapk1 
(Fig 12C, lower right).  
Fig 12 MAPK1 inhibition controls cardiac hypertrophy. (A) Schematic illustration of target  repression by 
miR-378 (left  panel), target de-repression by antimiR-378 treatment (center panel), and inhibition of the 
latter by short hairpin-mediated RNA interference on Mapk1 (right  panel). (B) Effect  of specific inhibition of 
the miR-378 target MAPK1 on antimiR-378-induced cardiomyocyte hypertrophy. (Left) Processed 
microscopic images of immunofluorescent staining of cardiomyocytes with an antibody against alpha-actinin 
(green cells). Scale bar=100 µm. (C) (Upper panel) Immunodetection of MAPK1 and MAPK3 on Western 
blot after knockdown of MAPK1 in NRCM by adenovirus-delivered shRNA. (Lower panel) Quantification 
of the data in (B) from three independent  experiments performed in triplicate.Statistical significance was 
determined by 2-way ANOVA and Bonferroni test  (C). Statistical significance is shown as 
*P<0.05,**P<0.01, ***P<0.001, or NS.
4.5.2 Inhibition of target derepression using short interfering RNAs
The strategy outlined in Fig 12A was tested for all four miR-378 targets using a short interfering 
RNA (siRNA) to inhibit  the target derepression by antimiR-378 (Fig 13A). The siRNAs against 
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Grb2, Igf1R, Ksr1 and Mapk1 were able to efficiently silence their mRNA expression (Fig 13B). 
Functional relationship of the four targets with miR-378 with respect to hypertrophy  was assessed 
by simultaneously transfecting NRCMs with antimiR-378 and each of the four siRNAs. The 
siRNAs against all four targets were able to efficiently inhibit the prohypertrophic response of 
antimiR-378 (Fig 13C) suggesting that the inhibition of the four targets by miR-378 was indeed 
responsible for the reduction in myocyte growth. 
Fig 13 Inhibition of the four factors  of MAPK pathway controls cardiomyocyte hypertrophy in 
NRCM. (A) Schematic illustration of target  repression by miR-378 (left  panel), target  de-repression by 
antimiR-378 treatment (center panel), and inhibition of the latter by short interfering RNA interference on 
Grb2, Igf1r, Ksr1 and Mapk1 (right panel). (B) Effect  of specific inhibition of the four targets using siRNA 
on their respective mRNA levels. (C) Effect of specific inhibition of the four miR-378 targets on 
antimiR-378-induced cardiomyocyte hypertrophy. (Left) Processed microscopic images of 
immunofluorescent staining of cardiomyocytes with an antibody against  alpha-actinin (green cells). Scale 
bar=100 µm. (Right) Quantification of data (n=3; 3 replicates each). Statistical significance was determined 
by 2-way ANOVA and Bonferroni test (C). Statistical significance is shown as *P<0.05,**P<0.01, 
***P<0.001, or NS.
4.6 Cardiotropic expression of miR-378 in vivo
4.6.1 Exogenous expression of miR-378 using AAV9
Transthoracic aortic constriction-induced pressure overload leads to a decrease in miR-378 
expression in mice (Fig 7C). To assess the contribution of miR-378 downregulation on the cardiac 
phenotype an in vivo study was designed using AAV9 to exogenously restore the miR-378 levels in 
cardiomyocytes. Five week old C57BL/6 N mice were injected with AAV9-miR-378 or PBS via the 
tail vein followed by aortic banding (TAC) or sham surgery (where only the chest of the animals 
were opened). Three weeks later, echocardiographic measurements were performed after which the 
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mice were euthanized and analyzed (Fig 14A). Quantification of miR-378 expression in the mice 
showed a 2.5 fold increase in miR-378 expression in the sham mice that received AAV9-miR-378 
compared to the control (ctrl) group that received PBS (Fig 14B). After TAC, the control mice 
showed a decrease in miR-378 expression that was effectively compensated by  the AAV9-miR-378 
intervention (Fig 14B). The exogenous expression of miR-378 had no significant effect on 
expression of the opposite strand of miR-378 (i.e. miR-378-5p). TAC-induced pressure overload 
increased the ventricular weight of the control mice which was decreased in mice that received 
AAV9-miR-378 suggesting partial attenuation of cardiac hypertrophy in these mice (Fig 14C). 
Pulmonary  edema, an indirect  parameter of cardiac dysfunction characterized by increased lung 
weight was decreased in the mice that received AAV9-miR-378 after TAC (Fig 14D). The levels of 
two other antihypertrophic microRNAs, miR-1 and miR-133a were also quantified in these mice 
(Fig 14E††). qPCR data showed that AAV9-miR-378 intervention did not change the expression 
levels of the two miRs compared to the sham groups. This excludes the possible involvement of 
miR-1 and/or miR-133a in the partial attenuation of cardiac hypertrophy.
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†† Performed by Deepak Ramanujam
Fig 14. Cardiotropic expression of miR-378 prevents cardiac hypertrophy in vivo. (A) Experimental 
strategy for exogenous expression of miR-378 using AAV9 in mice. 5-week-old mice were infected with an 
AAV9 vector that encodes miR-378 and then subjected to thoracic aortic constriction (TAC; causing chronic 
pressure overload) or control surgery (sham). At  week 11, echocardiographic measurements were taken, and 
animals were euthanized for further analysis. (B) Quantification of miR-378 in mouse hearts showed that 
infection with AAV9–miR-378 effectively compensated for the disease-associated loss of miR-378 (open 
bars). (C) Effect of AAV9–mediated expression of miR-378 on left  ventricular (LV) hypertrophy (shown as 
ratio of ventricular weight to tibia length). (D) Effect of AAV9–miR-378 on lung weight as a measure of 
pulmonary congestion. (E) Quantification of miR-1 and miR-133a in mouse hearts. Group sizes for A-D are 
as follows: 5 or 11 sham-treated mice that  received AAV9–miR-378 or control, and 7 or 8 TAC-treated mice 
that received AAV9–miR-378 or control, respectively. All data were evaluated by 2-way ANOVA/Bonferroni 
posttest. Statistical significance is shown as *P<0.05,**P<0.01, ***P<0.001, or NS.
4.6.2 Effect of miR-378 restoration on cardiac function
Echocardiographic data were obtained and analyzed to assess cardiac function in the mice after 
TAC. The data showed increased left ventricular (LV) mass, LV internal diameter and LV volume 
after TAC in the control group  while the mice injected with AAV9-miR-378 showed reduced LV 
mass, LV internal diameter and LV volume (Fig 15A-C). Consequently, both fractional shortening 
and ejection fraction, impaired in the control group  after TAC were significantly  improved with 
AAV9 intervention (Fig 15D-E). The administration of AAV9-miR-378 significantly prevented 
cardiac dysfunction induced by  chronic pressure overload and partially attenuated cardiac 
hypertrophy. This was supported by the reduction in the mRNA levels of cardiac hypertrophic 
markers Nppa, Nppb and Myh7 in the mice that received AAV9-miR-378 compared to the control 
group after TAC (Fig 15F).
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Fig 15. AAV9-miR-378 intervention prevented cardiac dysfunction induced by chronic pressure 
overload. (A)-(E) Echocardiographic data on LV mass, LV internal diameter, LV volume, fractional 
shortening and ejection fraction from mice infected with AAV9–miR-378. (F) mRNA levels of the 
hypertrophy markers Nppa, Nppb, and Myh7 determined by qPCR. Group sizes for A-F are as follows: 5 or 
11 sham-treated mice that  received AAV9–miR-378 or control, and 7 or 8 TAC-treated mice that received 
AAV9–miR-378 or control, respectively. All data were evaluated by 2-way ANOVA/Bonferroni posttest. 
Statistical significance is shown as *P<0.05,**P<0.01, ***P<0.001, or NS.
To exclude a possible effect  of AAV9 on cardiac function in these mice, the PBS control group  was 
compared with AAV9-GFP injected mice. Five week old mice were injected with either PBS (ctrl) 
or AAV9-GFP followed by TAC or sham surgery after 3 weeks (experimental strategy was similar 
to Fig 14A). Cardiac function was assessed by echocardiographic analysis in both ctrl and AAV9-
GFP groups. Both the groups had similar LV weight and similar cardiac function (Fig 16). The 
control and AAV9-GFP groups had no significant difference in various parameters like LV internal 
chamber diameter, LV posterior wall thickness, fractional shortening, ejection fraction (Fig 16). 
Since the TAC induced hypertrophy is almost identical in both the groups, it can be concluded that 
the antihypertrophic effect  of AAV9-miR-378 was not an intrinsic property  of AAV9, but a specific 
response to miR-378 restoration in the mice.
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Fig 16. Assessment of parameters  for cardiac morphology and function indicates  no difference 
between AAV9-GFP and PBS-control. To test whether an intrinsic property of AAV9 causes the beneficial 
effects observed with AAV9-miR-378, a control construct for expression of GFP from an AAV9 vector was 
created (AAV9-GFP) and compared to a PBS control. 5 weeks-old wild type male mice were treated by tail 
vein injection with either AAV9-GFP (1 x 1012 genome copies/mouse) or PBS. After 3 weeks, thoracic 
aortic constriction (TAC) was performed. Echocardiographic analysis was performed at 11 weeks of age. 
Shown here are the LV weight/tibia length data for the two groups along with echocardiography data for 
fractional shortening, ejection fraction, LV internal diameter (systole and diastole) and LV posterior wall 
thickness (systole and diastole). Group sizes are: 12 and 4 sham-treated mice that received AAV9-GFP or 
PBS respectively, and 7 and 6 TAC-treated mice that received AAV9-GFP or PBS, respectively. 
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4.6.3 Immunohistochemical analysis of cardiac tissue in AAV9 treated mice
Morphometric analyses were performed on subendocardial myocardium to assess the inhibition of 
cardiac hypertrophy in the AAV9-miR-378 treated mice after TAC. Paraffin-embedded heart 
sections were stained for wheat germ agglutinin (WGA) to mark the cell borders and SYTOX green 
to mark the nuclei, followed by automated image processing. Only the cardiomyocytes sectioned in 
the short  axis with a central nucleus were used for quantification of myocyte cross sectional area 
and myocyte breath. The quantification showed a clear increase in the myocyte hypertrophy after 
TAC in the control group which was reduced in the AAV9-miR-378 group  (Fig 17A-B‡‡). Given the 
proapoptotic effect  of miR-378 in vitro, the extent of apoptosis in these mice was analyzed using 
TUNEL staining. AAV9-miR-378 intervention had no effect on apoptosis after TAC (Fig 17C-D). 
This suggests that the reduction in LV weight and LV mass is due to the antihypertrophic effect  of 
AAV9-based miR-378 restoration and not due to cell death.
The progression of heart failure is accompanied by  increased fibroblast proliferation leading to 
stiffening of cardiac muscle and impaired cardiac function. Although miR-378 is a cardiomyocyte 
enriched microRNA, indirect paracrine influences on fibroblast proliferation cannot be excluded. 
This can be assessed by staining for Collagen deposition using Sirius red. Paraffin embedded heart 
tissue was stained with fast green and Sirius red followed by automated quantification of the sirius 
red staining. Chronic pressure overload induced by TAC lead to increased interstitial fibrosis as 
seen by the increased Sirius red staining in the control group (Fig 17E-F). AAV9-miR-378 
intervention prevented TAC-induced increase in fibrosis, which is in agreement with reduced 
cardiac hypertrophy and improved function. 
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‡‡ Performed by Andrea Ahles
Fig 17. Immunohistochemical  analysis. (A) Analysis of cardiomyocyte hypertrophy in cardiac tissue 
sections stained with WGA and SYTOX green. Individual cells were analyzed in an automated manner by 
pixel counting on digitized images. Scale bar=50 µm. (B) Quantitative analysis of cardiomyocyte (CM) 
cross-sectional areas and CM breadth (7 control-treated mice and 4–5 AAV9–miR-378–treated mice). (C) 
Exogenous expression of miR-378 does not  affect  cardiomyocyte apoptosis in vivo. Apoptosis was analyzed 
in paraffin sections of mouse hearts by TUNEL staining. Representative pictures of TUNEL staining in ctrl 
and AAV-miR-378-treated mouse hearts. (D) Quantification of apoptosis in hearts from mice that  had been 
infected with AAV-miR-378 after TAC (n=7 animals) or sham surgery (n=5). Data from non-infected sham- 
or TAC-treated control mice are shown in parallel (n=5 each with four fields of view per animal), scale bar = 
100 µm. (E) Quantification of interstitial fibrosis. Heart  tissue sections (left) stained with Sirius red/fast 
green in the AAV9–miR-378–treated and control group after sham or TAC treatment. (center) Representative 
images at  higher magnification. (F) Quantification of left  ventricular fibrosis determined from whole-heart 
sections. Group sizes for E-F are as follows: 5 or 11 sham-treated mice that  received AAV9–miR-378 or 
control, and 7 or 8 TAC-treated mice that  received AAV9–miR-378 or control, respectively. All data were 
evaluated by 2-way ANOVA/Bonferroni posttest. Statistical significance is shown as *P<0.05,**P<0.01, 
***P<0.001, or NS.
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4.6.4 Effect of miR-378 restoration on MAPK pathway factors
The effect  of exogenous expression of miR-378 on the four prohypertrophic targets was analyzed 
by quantifying their expression levels. Western blot and qPCR analysis of the four targets (Mapk1, 
Ksr1, Igf1r and Grb2) showed a marked upregulation of the four targets upon pressure overload in 
the control group (Fig 18 A-C). In contrast, the AAV9-miR-378 treated group showed significantly 
reduced protein levels of KSR1 and MAPK1 (Fig 18 A-B). The mRNA levels of Igf1r were also 
significantly reduced and a trend towards repression of the Grb2 mRNA levels was observed (Fig 
18C). The maintenance of physiological levels of miR-378 upon TAC inhibited the upregulation of 
the four prohypertrophic targets. The mRNA levels of two other published targets of miR-378 and 
miR-378* namely Crat and Med13102 respectively, were also analyzed by  qPCR (Fig 18D§§). The 
restoration miR-378 did not affect the expression of these two targets. Hence a correlation between 
these two targets and miR-378 is not evident in the heart. 
To summarize, the in vivo AAV9-miR-378 study clearly  demonstrates the antihypertrophic activity 
of miR-378 in cardiomyocytes together with a functional effect on four targets within the MAPK 
signaling cascade. miR-378 directly target the activation of MAPK signaling pathway upon 
pressure overload, at four distinct levels leading to reduced cardiac hypertrophy and improved 
cardiac function.
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§§ Performed by Deepak Ramanujam
Fig 18. Cardiotropic expression of miR-378 reduced four MAPK factors. (A) Western blot analysis of 
miR-378 target levels in the myocardium of TAC mice treated with AAV9–miR-378. Heat  shock protein 90 
(HSP90) served as a loading control. (B) Quantification of western blot  data. (C) qPCR analysis of mRNA 
levels of Igf1r and Grb2. (D) qPCR analysis of Med13 and Crat in myocardial tissue obtained from AAV9-
miR-378 treated mice and control mice after sham or TAC treatment. Group sizes are: 5 sham-treated mice 
that received AAV9-miR-378 or PBS, and 7 and 5 TAC-treated mice that  received AAV9-miR-378 or PBS, 
respectively. All data were evaluated by 2-way ANOVA/Bonferroni post  test. Statistical significance is 
shown as *P<0.05,**P<0.01, ***P<0.001, or NS.
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5 DISCUSSION
MicroRNAs have emerged as key regulators of gene expression during the progression of heart 
failure. MiR-378 is a muscle-enriched microRNA that is deregulated in the failing heart. In this 
study we elucidated the role of miR-378 in regulating cardiac hypertrophy, both in vitro and in vivo.  
5.1 MiR-378 and hypertrophy
The antihypertrophic effect of miR-378 combined with its downregulation in the failing heart 
suggests a cardioprotective role for this microRNA. Another study in primary cultures of 
cardiomyocytes also corroborated the antihypertrophic effect of miR-378 under PE stimulation, 
while identifying Grb2 as a miR-378 target103. The study showed that miR-378 overexpression in 
primary cultures of cardiomyocytes blocked PE-induced Ras activity  preventing the activation of 
ERK/MAPK and PI3-AKT signaling cascades downstream of Ras as well as blocking PE-induced 
phosphorylation of S6 ribosomal kinase, pGSK-3β and nuclear accumulation of NFAT. These 
observations are in line with the results of our current  study. Apart  from studying the role of 
miR-378 in primary cardiomyocytes we have also verified our results in vivo in a mouse model of 
chronic pressure overload (TAC). The downregulation of the microRNA under failing conditions in 
the heart could lead to insufficient control thereby further exacerbating myocardial hypertrophy. 
Downregulated miR-378 expression in these mice and increased myocyte size demonstrate the 
exacerbating effect of the insufficient control. When this control is re-exerted via compensation of 
the microRNA using an adeno-associated virus 9 construct, the progression of the hypertrophy and 
loss of function is halted leading to significant recovery of the mice.
5.2 MiR-378 and cardiac fibrosis
Extracellular fibrillar collagen functions as scaffolding tissue for the maintenance of cardiac 
structure6. Another important hallmark of the failing heart is the increased collagen deposition along 
with myocardial hypertrophy. The TAC mice show increased interstitial fibrosis, thus further 
contributing to ventricular dysfunction. The restoration of miR-378 in these mice via AAV9 showed 
a near complete attenuation of fibrosis, thus helping in the restoration of cardiac function. Even 
though miR-378 is enriched within cardiomyocytes, a paracrine effect of the miR cannot be 
excluded. Thus, a restoration of the lost miR-378 in the TAC mice led to reduced accumulation of 
myocardial fibrillar collagen.
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5.3 MiR-378 and apoptosis
There are contradictory reports on the role of miR-378 in apoptosis, which can be resolved to some 
extent with the results of this study. A study conducted in H9c2 cells showed attenuation of 
ischemia-induced apoptosis by caspase-3 inhibition under miR-378 overexpression83. Another study 
in primary cardiomyocyte cultures showed increased apoptosis levels under miR-378 
overexpression suggesting a proapoptotic role of the miR in primary cultures84. This discrepancy 
could be attributed to the type of cells used in the studies (H9c2 versus primary  cardiomyocyte 
cultures). Our study confirms a proapoptotic role of miR-378 in primary  cardiomyocyte cultures. 
However, a more definite approach would be to determine the effect  of the miR in vivo. Our study 
clearly  showed that miR-378 does not promote apoptosis in mice. The restoration of miR-378 levels 
via AAV9 showed no discernible increase in apoptosis which is in line with the improved cardiac 
function observed in these mice. Primary cardiomyocyte cultures often show increased sensitivity to 
apoptotic stimuli, which is not observed in vivo104. In vitro experiments involving transfection of 
synthetic miR-378 mimics lead to very high cellular levels of microRNA. In vivo experiments with 
the AA9 constructs lead to the restoration of miR-378 to normal physiological levels unlike 
transfection in an in vitro setting.
5.4 Hypertrophy and Mapk1/3
A key target of miR-378 is Mapk1, which along with Mapk3 is central signal transduction node. The 
role Mapk1/3 in cardiac hypertrophy is under much debate. Experiments conducted in primary 
neonatal rat cardiomyocytes show Mapk1/3 activation in response to agonist stimulation or cell 
stretching105-107. The essential role of Mapk1/3 signaling was further demonstrated using antisense 
oligonucleotides to prevent PE-induced cardiomyocyte hypertrophy108. Endothelin-1 and PE-
induced hypertrophy was blocked in studies in NRCM  using dominant negative Map2k1 or Raf1 
cDNA further suggesting a requirement of Map2k1-Mapk1/3 activation for the initiation or effective 
progression of hypertrophy in culture109,110. Mapk1/3 activation is also observed in chronic pressure 
overload stimulation induced by aortic banding in mice111. Genetic studies conducted in Mapk3-/- 
and Mapk1+/- mice as well as in transgenic mice with inducible expression of an Mapk1/3-
inactivating phosphatase in the heart (dual-specificity phosphatase 6) induced apoptosis and heart 
failure in mice but had no effect on hypertrophy112. More recently, in vivo and in vitro studies with 
mice lacking Mapk1/3 or overexpressing Map2k1 showed that Mapk1/3 regulated the balance 
between eccentric and concentric cardiac growth113. Our present study cannot resolve the open 
questions but it appears that the control over MAPK1/3 levels exerted by miR-378 reduced cardiac 
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hypertrophy  induced by pressure overload. This leads to further speculation that miR-378 might 
play  an important role in fine tuning the activation of MAPK1/3 cascade during the initiation and 
progression of hypertrophy and further, a timely intervention by  means of an AAV9 miR-378 
construct helps regain the control lost  due to the downregulation of mir-378 levels in the failing 
heart.
5.5 Ksr1
Apart from Mapk1, miR-378 also directly targets Ksr1. KSR1 is a scaffold protein that brings 
together the various components of the ERK/MAPK cascade114. KSR proteins contain five 
conserved domains (Fig 19)115: CA1, which is unique to KSR1 and lacking in KSR2; CA2, a 
proline-rich sequence; CA3, a cysteine-rich domain that mediates interactions with membrane 
lipids; CA4, a serine/threonine-rich region that binds extracellular signal-regulated kinase/mitogen- 
activated protein kinase (ERK/MAPK); and CA5, the putative kinase domain. C-TAK1 binds to the 
N-terminal region and phosphorylates the 14-3-3 docking sites S297 and S392. MAPK and MAP2K 
(MEK) and RAF bind to the C-terminal region that contains the CA5 domain. RAF kinases share 
three conserved regions: CR1, a cysteine-rich domain that contains part of the Ras-binding domain 
and also interacts with membrane lipids; CR2, a serine/threonine rich region that forms part of the 
MST2 (mammalian sterile-twenty-like-2) binding region; and CR3, the kinase domain, which can 
bind MAP2K. 
Fig 19. Conserved domains in KSR1 (Illustration from Kolch 2005)
Binding of 14-3-3 proteins to S392 in KSR or S259 in RAF1 sequesters KSR1 and RAF1 in the 
cytosol (Fig 20). The kinase activity of KSR1 is yet unclear although several studies have 
conclusively  support  its kinase-independent function as a molecular scaffold. Studies have shown 
that cooperation of KSR1 protein with Ras to transform cells required the cysteine-rich CA3 
domain in the non-catalytic region, but not the KSR1 kinase domain suggesting a scaffolding role 
for KSR1116.
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localization11. So, kinase-independent scaffolding func-
tions of Raf-1 contribute to the physiological functions 
that connect Raf-1 with pathways that control both 
apoptosis and cytoskeletal dynamics.
Kinase suppressor of Ras-1 
Kinase suppressor of Ras-1 (KSR1) was originally 
found in genetic screens in Drosophila melanogaster 
and Caenorhabditis elegans as a suppressor of an 
activated Ras phenotype14. KSR1 has high homology 
with Raf-1 (FIG. 1), but its kinase domain has mutations 
in key residues that are essential for catalytic activ-
ity in other protein kinases. Whether or not KSR1 
possesses kinase activity has not been conclusively 
settled, although the bulk of evidence supports a 
kinase-independent function of KSR1 as a scaffold of 
the ERK/MAPK pathway.
KSR1 and the ERK/MAPK pathway. KSR1 can bind 
all kinase members of the ERK/MAPK pathway but, 
whereas MEK is associated constitutively, Raf-1 and 
ERK/MAPK might bind in a stimulus-dependent 
manner14. Strong evidence that KSR1 is a scaffold pro-
tein stems from experiments showing that cooperation 
of this protein with Ras to transform cells required the 
cysteine-rich CA3 domain in the non-catalytic region, 
but not the KSR1 kinase domain15. Titrating the levels of 
KSR1 expression affects ERK/MAPK pathway signalling 
in a bell-shaped-curve manner that is typical of scaffold-
ing proteins16. That is, an increase in scaffold expression 
enhances the assembly of signalling-competent com-
plexes until the concentration of the scaffold exceeds that 
of its client proteins, causing them to bind individually 
rather than to the same molecule at the same time, thereby 
effectively dissipating protein complexes and inhibiting 
signalling. In Ksr1–/– fibroblasts, re-expression of KSR1 at 
~14-fold higher levels than normal resulted in maximal 
assembly of the Raf-1–MEK–ERK/MAPK complex and 
optimal ERK/MAPK signalling. However, even under 
these conditions, less than 5% of endogenous Raf-1, 
MEK or ERK/MAPK was associated with KSR1 REF. 16, 
which indicates that, instead of globally enhancing 
ERK/MAPK signalling, KSR1 might affect only a subset 
of functions.
Insights from Ksr-knockout mice. In C. elegans both 
KSR-1 and KSR-2 isoforms are involved in distinct devel-
opmental pathways, and only their double knockout is 
lethal17. In mice, the knockout of Ksr1 causes defects in 
antigen-triggered T-cell proliferation18 and disorganized 
hair follicles19. The subtlety of the phenotype might be 
deceptive, as a recently identified relative, KSR2 REF. 20, 
might compensate for the loss of KSR1. Importantly, 
Ksr1–/– mice are less susceptible to oncogene-induced 
tumours than their wild-type counterparts16,18,19, which 
implies that KSR1 supports the proliferative and trans-
forming functions of the ERK/MAPK pathway. This 
is consistent with the notion that ablation of KSR1 
abolishes the sustained activation of ERK/MAPK that 
is required for mitogenesis16,21. Ksr1–/– mice also have an 
elevated basal level of apoptosis of colon epithelial cells, 
which manifests itself pathologically when these cells 
are challenged by tumour necrosis factor-α (TNFα)22. 
This correlates with a lack of ERK/MAPK activation 
by TNFα. Similarly, overexpression of B-KSR, a tissue-
specific KSR1 splice form, converts epidermal growth 
factor (EGF) from a weakly proliferative signal into a 
differentiation signal for PC12 cells by extending the 
duration of ERK/MAPK signalling (which is required 
for neuronal differentiation)23. These data indicate that 
KSR1 can influence the biological fate of cells by regulat-
ing the activation kinetics of the part of the ERK/MAPK 
pathway that mediates proliferation, transformation, 
differentiation and apoptosis.
Regulating the scaffold. If KSR1 is the crucial denomina-
tor, the question then arises — what regulates the scaf-
fold? In response to growth factors, KSR1 is translocated 
to the cell membrane (FIG. 2). This promotes MEK activa-
tion, presumably by presenting MEK to activated Raf24. 
In quiescent cells, KSR1 is retained in a Triton-insolu-
ble compartment by the protein ‘impedes mitogenic 
signal propagation’ (IMP)25 and in the cytoplasm by 
1433 PROTEINS that dock to the serine-phosphorylated 
residues 297 and 392 REF. 24. S392 is phosphorylated by 
Cdc25C-associated kinase-1 (C-TAK1)24 and nucleo-
side diphosphate kinase, mitochondrial-23 (Nm23)26. 
Mitogens induce the dephosphorylation of S392 by 
protein phosphatase-2A (PP2A)24 and the destruction of 
IMP25, which is sufficient to enable KSR1 to translocate 
to the cell membrane.
The KSR cycle. IMP is an E3 UBIQUITIN LIGASE that triggers 
its own degradation when it is bound by Ras•GTP25. 
However, in non-stimulated cells, instead of ubiquity-
lating KSR1, IMP causes KSR1 hyperphosphorylation, 
Figure 1 | KSR and Raf domains. KSR (kinase suppressor of Ras) proteins contain five 
conserved domains: CA1, which is unique to KSR1 and lacking in KSR2; CA2, a proline-rich 
sequence; CA3, a cysteine-rich domain that mediates interactions with membrane lipids; 
CA4, a serine/threonine-rich region that binds extracellular signal-regulated kinase/mitogen-
activated protein kinase (ERK/MAPK); and CA5, the putative kinase domain. Binding sites for 
some interacting proteins are indicated. C-TAK1 binds to the N-terminal region and 
phosphorylates the 14-3-3 docking sites S297 and S392. MAPK and ERK kinase (MEK) and 
Raf bind to the C-terminal region that contains the CA5 domain. Raf kinases share three 
conserved regions: CR1, a cysteine-rich domain that contains part of the Ras-binding domain 
and also interacts with membrane lipids; CR2, a serine/threonine rich region that forms part of 
the MST2-binding region; and CR3, the kinase domain, which can bind MEK. Binding of 
14-3-3 proteins to S392 in KSR or S259 in Raf-1 sequesters KSR1 and Raf-1 in the cytosol. 
MST2, mammalian sterile-twenty-like-2.
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Fig 20. The KSR regulation cycle (Illustration from Kolch 2005)
KSR1 scaffolds the three-tiered RAF–MEK–ERK module (Fig 20). Studies have shown that 
titrating the levels of KSR1 expression affects ERK/MAPK pathway signaling in a bell-shaped-
curve manner. That is, an increase in KSR1 expression enhances the assembly  of the module until 
the concentration of the scaffold exceeds that of its client proteins causing them to bind individually 
rather than forming a complete signaling module117.
Studies in KSR deficient mice showed that  KSR1 facilitated MAPK activation by  enhancing the 
Ras/MAPK signaling pathway118. In response to growth factors, KSR1 is translocated to the cell 
membrane leading to MEK activation, by facilitating an interaction with activated Raf119. In 
quiescent cells, KSR1 is retained in a Triton insoluble compartment by  the protein ‘impedes 
mitogenic signal propagation’ (IMP)120 and in the cytoplasm by 14-3-3 proteins that dock to the 
serine-phosphorylated residues 297 and 392. S392 is phosphorylated by Cdc25C-associated 
kinase-1 (C-TAK1)119 and nucleoside diphosphate kinase, mitochondrial-23 (Nm23)121. Growth 
stimulus induces the dephosphorylation of S392 by protein phosphatase-2A (PP2A) and the 
destruction of IMP that enables the translocation of KSR1 to the cell membrane. In mice, the 
knockout of Ksr1 causes defects in antigen-triggered T-cell proliferation and disorganized hair 
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DOMINANT NEGATIVE 
A defective protein that retains 
interaction capabilities and so 
competes with normal proteins, 
thereby impairing protein 
function.
STERILE αMOTIF 
(SAM). Domain of ~70 amino 
acids roughly conserved in 
many proteins and thought to 
participate in protein–protein 
interactions. 
which sequesters KSR1 into a Triton-insoluble com-
partment25. Neither the phosphorylation site(s) nor the 
responsible kinase(s) are known. Whereas EGF induces 
the dephosphorylation of S392 REF. 24, transfection of 
activated Ras induces KSR1 phosphorylation on T260, 
T274 and S443 REF. 27. Mutation of S392 and T274 
stabilizes KSR1, which implies that phosphorylation 
of these residues normally exerts negative feedback on 
protein stability21. So as coordinates several aspects 
of KSR1 function. Whereas activated Ras neutralizes 
the effect of the functional KSR1 inhibitors 14-3-3 
and IMP, it also induces the phosphorylation of T274, 
a site that primes KSR1 for degradation. The twist is 
that phosphorylated T274 only promotes KSR1 degra-
dation in conjunction with phosphorylated S392, but 
S392 is dephosphorylated in response to Ras activation. 
Re-phosphorylation of S392 enables 14-3-3 to bind 
again, thereby returning KSR1 to the cytosol. The 
concomitant presence of phosphorylated T274 would 
mark these KSR1 molecules for degradation, permit-
ting the selective removal of KSR1 molecules that have 
participated in the mitogen-induced scaffolding and 
enhancement of the ERK/MAPK pathway. Mutating 
T274 and S392 to residues that cannot be phosphory-
lated extends ERK/MAPK activation and greatly 
enhances the mitogenic abilities of EGF21. The interplay 
and, in particular, the timing between these processes 
generates a combinatorial controller for modulating 
both the amplitude and duration of ERK/MAPK 
activity. This example demonstrates that even a simple 
system can generate complex behaviour when timing 
and spatial effects are taken into account.
Connector enhancer of KSR 
Connector enhancer of KSR (CNK) was identified in 
a genetic screen in D. melanogaster as an enhancer of 
the DOMINANT NEGATIVE phenotype caused by the isolated 
KSR kinase domain28. CNK has no catalytic motifs, but 
it does have several protein interaction domains, includ-
ing — starting from the N terminus — a STERILE αMOTIF 
(SAM); a conserved region in CNK (CRIC); a PSD-95, 
Dlg and ZO1 PDZ DOMAIN; and, nearer the C-terminal, 
proline-rich Src-homology-3 (SH3)-binding sites and 
PLECKSTRIN HOMOLOGY PH DOMAINS (FIG. 3). This indicates a 
potential function as a multivalent adaptor protein.
CNK and ERK/MAPK signalling. D. melanogaster 
genetic analyses placed CNK function downstream of 
receptor tyrosine kinases (RTKs) and Ras, but upstream 
or parallel to Raf28. In D. melanogaster, CNK regulates 
Raf by a complex mechanism. In genetic EPISTASIS 
ANALYSES, the CNK C-terminal Raf-interaction domain, 
later narrowed down to the Raf inhibitory region, RIR 
(present only in D. melanogaster CNK (FIG. 3a))29, pre-
vented the disturbances in eye development that are 
caused by activated Ras and Raf. By contrast, the CNK 
N-terminal domain cooperated with activated Ras, 
but not with activated Raf, which implies that CNK 
exerts complex effects on Ras signalling that include 
Raf activation, and could also affect other Ras effec-
tor pathways30. Subsequent biochemical analysis in 
D. melanogaster S2 cells showed that D. melanogaster 
CNK mediates Raf activation by Ras through its SAM 
and CRIC domains in the N terminus, but inhibits 
Raf through the RIR in the C terminus29. This coun-
terintuitive combination of a Raf-activating and 
Raf-inhibitory motif in the same scaffold presumably 
functions to filter signal from noise by suppressing 
background phosphorylation of MEK by Raf29.
Activation of RTKs or Ras results in the release of 
RIR-mediated repression of Raf, which permits efficient 
Ras-mediated activation of Raf and MEK phosphoryla-
tion to proceed. The mechanism has been traced to the 
RTK-induced binding of SRC42 (a D. melanogaster 
homologue of mammalian Src) to a region of CNK that is 
just C-terminal to the RIR. Curiously, this derepression 
does not require SRC42 catalytic activity, but depends 
Figure 2 | The KSR regulation cycle. Inactive kinase suppressor of Ras (KSR) is sequestered 
in the cytosol a d in a Triton-insoluble compartment by binding to 14-3-3 and by the protein 
‘impedes mitogenic signal propagation’ (IMP)-induced phosphorylation. As the exact 
differences between KSR in these populations are unknown, KSR is depicted as one entity in 
the figure. On stimulation by mitogens such as epidermal growth factor (EGF), activated 
receptors recruit Ras guanine nucleotide-exchange factors, such as son of sevenless (SOS) 
through the adaptor protein growth-factor-receptor-bound-2 (Grb2), which generates 
Ras•GTP. Ras•GTP induc  KSR dephosphorylation of S392 by s imul ting the binding of the
protein phosphatase-2A (PP2A) B subunit to its A and C subunits, which are constitutively 
associated with KSR. This results in the r leas  of 14-3-3 from this KSR binding site and 
translocation of KSR to the cell membrane. The binding of active Ras to IMP triggers IMP 
autoubiquitylation and its subs quent degradation. KSR facili ates the phosphorylation f 
MAPK and ERK kinase (MEK) by Raf, and enhances the generation of activated extracellular 
signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK), which can 
phosphorylate both nuclear and non-nuclear substrates. The inactivation of KSR involves 
Ras-induced phosphorylation (not shown), re-phosphorylation of the 14-3-3-binding site S392 
by C-TAK1 or Nm23, and presumably the reassociation of KSR with IMP and phosphorylation 
by an unknown kinase that is recruited by IMP.
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follicles115. Importantly, Ksr1–/– mice are less susceptible to oncogene-induced tumours than their 
wild-type counterparts115, implying that KSR1 supports the proliferative and transforming functions 
of the ERK/MAPK pathway. This is consistent  with the notion that ablation of KSR1 abolishes the 
sustained activation of ERK/MAPK that is required for mitogenesis. Cardiac specific Ksr1 deletion 
has not yet been reported.
5.5.1 Hypertrophy and KSR1
Until now there have been few reports highlighting the role of KSR1 in the regulation of 
hypertrophy. Experiments involving siRNA against KSR1 in our study  clearly  showed a correlation 
between the abolition of the antimiR-378 induced hypertrophy with KSR1 inhibition suggesting in 
its involvement in the regulation of cardiac hypertrophy. Interestingly, other proteins linked to 
KSR1 and Ras signaling have been shown to regulate cardiac hypertrophy.
CNK - RASSF1
Connector enhancer of KSR (CNK) was identified in a genetic screen in D. melanogaster as an 
enhancer of the dominant negative phenotype caused by the isolated KSR kinase domain122. Studies 
show that CNK functions downstream of receptor tyrosine kinases (RTKs) and Ras, but upstream or 
parallel to RAF122. CNK coordinates other signaling pathways by interacting with many  proteins 
that include: RAL (Ras-like protein) and its exchange factors, Ral guanine nucleotide dissociation 
stimulator (Ral-GDS) and RalGDS-like factor (RLF); Ras-association domain family-1 (RASSF1), 
and Rho, through which CNK1 selectively  enhances Rho stimulated transcription115,122,123. Ras is a 
family of low-molecular-weight guanine nucleotide binding proteins that has long been associated 
with hypertrophy124. RASSF1 is a member of the RASSF family of tumor suppressor proteins that 
consist of at least  10 different proteins, RASSF1-10. Seven isoforms of RASSF1 have been 
recognized, RASSF1A through RASSF1G, which are derived from alternative splicing and different 
promoter usage125. RASSF1A has been described as a pivotal protein in regulating cardiac 
hypertrophy  in mouse. Its absence causes increased hypertrophy and remodeling under conditions 
of sustained mechanical stress by increased activation of the MAPK1/3 signaling pathway. 
5.6 Hypertrophy and IGF1R
The insulin signal transduction pathway is an important player in cardiac growth regulating several 
aspects of cellular physiology and growth. IGFs are secreted polypeptides that act  by binding to 
tyrosine kinase receptors126. They  usually circulate in the bloodstream and extracellular space 
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mediating endocrine and/or paracrine effects on numerous signal transduction networks. They are 
produced throughout the body especially in the liver, skeletal muscle and heart. 
The GH - IGF axis
Growth hormone (GH) is a key regulator of growth in animals. GH stimulation leads to activation 
of IGF-1 secretion in local tissues leading to metabolic and growth promoting effects and 
stimulation of protein synthesis. IGF-1 mediates many of the effects of growth hormone (GH) on 
peripheral tissues127. Any interference in this signaling axis can have profound cardiac 
manifestations. A very specific cardiomyopathy has been described in a majority of patients with 
acromegaly (increased serum GH and IGF-1 levels), characterized by biventricular concentric 
myocardial hypertrophy  with interstitial fibrosis, lympho-mononuclear infiltration and areas of 
monocyte necrosis128. This suggests that IGF-1 may be important in the development of ventricular 
hypertrophy. 
IGFs are characterized by a signal peptide, a B-chain, a C-peptide, and an A-chain. The C-peptide 
of the propeptide is proteolytically  cleaved and two disulfide bonds between the A- and B-chains, 
and a third disulfide bond within the A-chain are present in the mature peptide. In mammalian 
IGF-1 and IGF-2, the C-peptide is retained in the mature peptide129. 
The IGF-1 receptor (IGF1R) is assembled in a β–α–α–β structure that is similar to that of the insulin 
receptor. The difference between the two receptors lies in the extracellular α subunit that  controls 
the ligand binding specificity  of the receptor130. IGF1R can be activated by the binding of both 
IGF1 and IGF2.
A number of studies have described a role of IGF1 in the development of cardiac hypertrophy. 
Studies have shown that mild or short-term overload-induced physiological hypertrophy where the 
heart enlarges until it  establishes a new operational plateau. Severe and/or sustained overload lead 
to pathological hypertrophy, characterized by increased fibrosis and decreased cardiac output (Fig 9 
and Fig 11E-F). Transverse aortic constriction lead to activation of the IGF1-IGF1R autocrine axis 
accompanied by an increase in the mRNA levels of IGF1131 and IGF1R (Fig 12C). IGF1 has been 
implicated to be the primary  factor contributing to the development of cardiac hypertrophy under 
conditions of pressure overload132. It  has also been described that IGF-I-stimulated collagen 
production in primary cultures of mechanically  loaded cardiac fibroblasts133. This is consistent with 
increased cardiac fibrosis observed in patients with acromegaly and increased IGF1 stimulation. 
Sustained expression of IGFI in a transgenic mouse model initially  induced an analog of 
physiologic hypertrophy, characterized by increased cardiac mass and improved systolic 
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performance. However, later this hypertrophy progressed to a pathological condition characterized 
by decreased systolic performance and increased interstitial fibrosis134. IGF1 has been reported to 
be a direct target of miR-1. Consequently, pressure overload-induced downregulation of miR-1 ia 
accompanied by IGF1 upregulation135(Fig 8E).
In our study Igf1r has been clearly shown to be a target of miR-378, which is also described by 
other studies84. Transgenic mice overexpressing Igf1r in the heart displayed cardiac hypertrophy 
with increased myocyte size though there was no evidence of histopathology136. These mice also 
displayed enhanced systolic function at 3 months of age maintained until 12–16 months of age. The 
phosphoinositide 3-kinase (PI3K)-Akt- p70S6K1 pathway was found to be significantly activated in 
hearts from these transgenic mice. Cardiac hypertrophy  induced by overexpression of IGF1R was 
completely blocked by a dominant  negative PI3K mutant, suggesting that IGF1R promoted 
compensated cardiac hypertrophy in a PI3K dependent manner. Analysis of MAPK1/3 signaling in 
these mice showed increased phosphorylation as well as increased total MAPK1 levels. The IGF1-
PI3K axis has been implicated in physiological hypertrophy, while the Gaq pathway is supposed to 
regulate pathological hypertrophy137. This distinction however, does not seem completely 
consistent. The activation of MAPK1/3 signaling in IGF1R transgenic mice suggest a possible 
interaction between the two pathways. Our current study suggests a clear role of IGF1R in 
pathological cardiac hypertrophy both in vitro as well as in vivo. The regulation of IGF1R by 
miR-378 contributes to the protective effect of miR-378 compensation under pressure overload-
induced pathological hypertrophy. This accompanied by  the fact that sustained IGF1 expression 
lead to pathological cardiac hypertrophy overtime further suggests the involvement of IGF1-IGF1R 
activation in pathological cardiac hypertrophy. This hypothesis is further supported by studying 
another miR, namely miR-1 in a similar scenario. miR-1 has been shown to directly target both 
IGF1 and IGF1R135 and negatively regulate hypertrophy. 
AKT is a serine/threonine protein kinase, primarily regulated by PtdIns(3,4,5)P3-mediated 
membrane recruitment and by PDK1 activity. PI3K-dependent PDK1 activation leads to direct 
AKT phosphorylation at Thr308. There are three genes encoding AKT namely, Akt1, Akt2 and 
Akt3 . Of the three, Akt1 and Akt2 are the main cardiac isoforms. Akt1 null mice showed impaired 
growth and resistance to exercise induced cardiac hypertrophy138. Similarly, overexpression of a 
dominant negative AKT1 mutant in the heart inhibited physiological hypertrophy. Cardiac 
overexpression of constitutively  active AKT1 mutant initially  promoted physiological hypertrophy 
that eventually  progressed to pathological hypertrophy139,140. This suggests that the role of AKT in 
hypertrophy  is dependent on the magnitude of AKT1 activation and its cellular location. Also, in 
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another study, overexpression of AKT led to a decrease in miR-1 expression levels suggesting that 
the PI3-AKT cascade need not always be protective135. Perhaps microRNAs like miR-378 and 
miR-1, mediate the fine tuning of AKT and MAPK signaling cascades and balance their adaptive 
and maladaptive features. 
5.7 Hypertrophy and Grb2
GRB2 is a scaffolding protein composed of two Src-homology type 3 (SH3) domains flanking a 
single SH2 domain141,142. The SH3 domains bind to polyproline peptide motifs on the Ras guanine 
nucleotide exchange factor SOS. The SH2 domain of Grb2 binds to phosphotyrosine motifs present 
on activated FAK, Shc, and receptor tyrosine kinases. Grb2 knockout mice are unable to form 
epiblast and display defective endoderm differentiation, due to which they  do not survive 
embryonic development. However, Grb2 haploinsufficient mice are able to survive embryogenesis 
and appear normal at birth143. Biomechanical stress during cardiac pressure overload is mediated 
through integrins that trigger downstream molecules like activation of tyrosine kinase FAK and 
small GTPase Ras and the subsequent recruitment of adapter protein GRB2, which in turn can 
activate various MAPK cascades via the Ras guanine nucleotide exchange factor SOS144. Grb2 
haploinsufficient mice showed attenuated p38 MAPK and JNK activation, but not ERK activation 
suggesting a differing dose response thresholds of various MAPK cascades to Ras activation145. 
Raf-1 activation may require a relatively small amount of Ras-GTP loading since the MAPK kinase 
kinase(MAPKKK) directly binds to Ras unlike other p38 and JNK that do not directly bind to Ras 
and instead are dependent upon other intermediary proteins. Our study supports this view since our 
results show that inhibition of GRB2 along with the other factors in ERK/MAPK cascade is able to 
attenuate ERK activation.
Grb2 haploinsufficient mice did not develop cardiac hypertrophy or fibrosis in response to pressure 
overload145. Also, transgenic mice expressing dominant negative forms of p38 MAPK in the heart 
developed cardiac hypertrophy but  not  fibrosis after pressure overload despite markedly reduced 
p38 MAPK suggesting that cardiac hypertrophy and fibrosis is dependent upon a signal 
transduction pathway that includes GRB2 but not p38 MAPK. These observations clearly 
demonstrate the importance of GRB2 in pressure overload mediated cardiac hypertrophy and 
fibrosis. Our current study supports these results further demonstrating the prohypertrophic role of 
GRB2 both in culture and in mice. Inhibition of GRB2 using an siRNA protected NRCMs against 
the prohypertrophic effect of antimiR-378. In mice, the AAV-miR-378 intervention re exerted the 
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control over pressure overload-induced activation of MAPK cascade by  the regulation of GRB2 
levels.
5.8 Downregulation of miR-378 in the failing heart
The location of miR-378 within the first intron of the gene Ppargc1b and its cotranscription with 
the transcriptional coactivator PGC1β suggests a possible interconnection between the two. Another 
interesting observation is the downregulation of PGC1β during heart failure. The downregulation of 
miR-378 in the failing heart could be attributed to the downregulation of PGC1β. The PGC1 family 
of coactivators are a class of extensively  researched regulators of metabolic pathways. They work 
as inducible coregulators of nuclear receptors regulating metabolic pathways controlling cellular 
energy146. Coactivators, PGC-1α and PGC1β and the nuclear receptors estrogen-related receptors α 
and γ (ERRα and γ) form a key  signaling node responsible for the regulation of cardiac genes 
involved in multiple mitochondrial energy transduction and ATP-generating pathways147. Members 
of the nuclear receptor superfamily relay  physiologic and nutritional cues to critical gene regulatory 
responses. The molecular links between external stimuli, cellular signaling events, and nuclear 
receptor-mediated transcriptional control has multiple implications in the failing heart146. Nuclear 
receptors receive regulatory input through multiple mechanisms including levels of endogenous 
ligand, availability of heterodimeric nuclear receptor partners, and posttranslational modifications. 
Activating signals trigger the recruitment of coactivator complexes onto the nuclear receptor 
platform, leading to enzymatic modification of chromatin, increased access of the RNA polymerase 
II machinery to RNA, and activation of target gene transcription. Availability  of PGC1 family of 
coactivators serve critical regulatory functions linking physiologic stimuli to nuclear receptor 
activity. 
PGC-1α and PGC-1β are preferentially expressed in tissues with high oxidative capacity, such as 
heart, slow-twitch skeletal muscle, and BAT, where they serve critical roles in the regulation of 
mitochondrial functional capacity and cellular energy metabolism. PGC-1 coactivator docking to 
specific transcription factors provides a platform for the recruitment of regulatory protein 
complexes that exert powerful effects on gene transcription148.
Mir-378 and miR-378* are coexpressed and coregulated with PGC-1β102,149. MiR-378* has been 
described as a molecular switch involved in the orchestration of the Warburg effect in breast cancer 
cells via interference with a well-integrated bioenergetics transcriptional pathway leading to a 
reduction in tricarboxylic acid cycle gene expression and oxygen consumption as well as an 
increase in lactate production and in cell proliferation149.
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MiR-378/miR-378* knockout mice showed resistance to high fat diet-induced obesity  and exhibited 
enhanced mitochondrial fatty acid metabolism indicating that they  were essential for the control of 
mitochondrial metabolism and systemic homeostasis102. Also, the two miRs were found to directly 
target carnitine O-acetyltransferase, a mitochondrial enzyme involved in fatty acid metabolism, and 
MED13, a component of the mediator complex that controls nuclear hormone receptor activity, 
respectively. Consequently, the two targets were reported to be elevated in the livers of the 
miR-378/miR-378* knockout mice. Interestingly, the authors did not find any  regulation of the two 
mRNAs in the hearts of the knockout mice. Also, the hearts of the knockout mice did not display 
increased fat or triglyceride accumulation or any other phenotype. Moreover, an analysis of the two 
targets in our current study showed no regulation in the hearts of the AAV-miR-378 treated mice 
(Fig 11D) suggesting that perhaps miR-378 regulates a different pool of targets in the heart.
5.8.1 Pgc1α and Pgc1β
Fuel and energy metabolic disturbances are a signature of cardiac hypertrophy and heart failure 150. 
The development of pathologic cardiac hypertrophy  due to pressure overload is associated with a 
relative increase in glucose utilization and reduction in fatty  acid oxidation and a shift towards a 
fetal metabolic profile151. This metabolic shift is related to the downregulation of expression and 
activity of PGC-1α, ERRα and downstream target genes. Since miR-378 and PGC-1β are 
coexpressed and coregulated, their downregulation may contribute to the metabolic shift. This 
metabolic shift may initially be an adaptive function to divert flux away from mitochondrial 
pathways, over the long-term this response is likely to be maladaptive leading to energy  starvation 
and heart failure152. The phenotype of PGC-1 loss-of-function mice demonstrates that  reduced 
PGC-1/ERR activity can lead to cardiac dysfunction153-155. Similarly, inhibiting PGC-1 expression 
via cardiac-specific overexpression of HDAC5 also produces a cardiomyopathy that is associated 
with mitochondrial abnormalities and myocardial lipid accumulation. 
PGC-1α overexpression in cardiac myocytes in vitro and in vivo in transgenic mice is sufficient to 
trigger mitochondrial proliferation suggesting the importance of PGC-1 coactivators in perinatal 
mitochondrial biogenesis156. Conversely, in mice with combined PGC-1α/β gene disruption, 
perinatal mitochondrial biogenesis is arrested and the mice die within days after birth from heart 
failure153. Together, these results indicate that the PGC-1 coactivators are necessary and sufficient 
for postnatal metabolic maturation and cardiac function. 
In pressure overload hypertrophy and heart failure, the repression of PGC-1α and its transcriptional 
partners is responsible for the shift away from fatty acid oxidation toward glucose oxidation and 
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impaired ATP production157. PGC-1α knockout mice show accelerated cardiac dysfunction and 
heart failure following pressure overload hypertrophy155. These  knockout mice show reduced 
expression of fatty acid oxidation and oxidative phosphorylation genes similar to wild type mice 
following pressure overload. This repression was more pronounced in banded PGC-1α knockout 
mice and coinciding with the onset of heart failure. These banded mice also show increased 
oxidative stress, which might further contribute towards accelerated heart failure158. All these 
observations suggest that perhaps a component of the mitochondrial dysfunction during the 
transition from compensated hypertrophy to heart failure might  be PGC-1α independent159. PGC-1β 
knockout mice showed reduced oxidative phosphorylation gene expression and palmitoyl-carnitine-
supported mitochondrial function but normal fatty acid oxidation. Following pressure overload 
hypertrophy  PGC-1β knockout mice exhibited higher oxidative stress, decreased cardiac efficiency, 
lower rates of glucose metabolism, and repression of hexokinase II protein thus showing that 
PGC-1β deficiency, like PGC-1α, accelerated the transition    to heart failure in pressure overload 
hypertrophy159. These studies suggest partially overlapping roles of PGC-1α and PGC-1β in 
maintaining mitochondrial energetics. 
5.8.2 The repression of PGC-1 in the failing heart
The shift  towards fetal metabolic profile during the development of cardiac hypertrophy is related 
to the repression of PGC-1 family, ERRα and their downstream target genes. M-CPT I and MCAD, 
are enzymes catalyzing the rate-limiting steps in the mitochondrial import and oxidation of fatty 
acids, respectively. Hypertrophy mediated by  the α1-adrenergic agonist PE, resulted in a decrease in 
M-CPT1 levels160. The M-CPT1 promoter activity was mapped to a peroxisome proliferator–
activated receptor-α (PPARα) response element that was reduced during both PE stimulation as well 
as during pressure overload in mice. This repression was found to be mediated at  the post 
transcriptional level via the ERK/MAPK pathway. The inhibition of the PE stimulated ERK/MAPK 
pathway activation using an inhibitor (PD98059) prevented the repression of fatty acid oxidation, 
while the inhibition of other MAPKs like JNK or p38 had no effect. Also, PPARα was found to be a 
direct target of ERK/MAPK via phosphorylation sites located in the NH2 terminal AB domain of 
PPARα. To summarize, during pathological hypertrophy, fatty acid oxidation is downregulated via 
the deactivation of PPARα and its coactivator PGC-1α by the action of ERK/MAPK pathway. 
The ERK-MAPK pathway has also been shown to phosphorylate and inhibit PPARγ activity in 
noncardiac cell lines161. Adipocyte differentiation is strongly inhibited by  many mitogens and 
oncogenes. Several growth factors that inhibit fat cell differentiation caused ERK/MAPK mediated 
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phosphorylation of the transcription factor PPARγ and reduction of its transcriptional activity. 
Expression of PPARγ with a nonphosphorylatable mutation at this site (serine- 112) yielded cells 
with increased sensitivity to ligand-induced adipogenesis and resistance to inhibition of 
differentiation by mitogens. Taking this into account, it  can be hypothesized that activation of the 
ERK/MAPK activity during hypertrophy is likely to result in the repression of PPARγ and its 
coactivator PGC-1β as in the case of PPARα and its coactivator PGC-1α.
Hypertrophy is accompanied by activation of cyclin T/Cdk9, which phosphorylates the C-terminal 
domain of the large subunit  of RNA polymerase II, stimulating transcription elongation and pre-
mRNA processing; CDK9 activity was required for hypertrophy in culture, whereas heart-specific 
activation of CDK9 by cyclin T1 provoked hypertrophy in mice162. At pathophysiological levels, 
Cdk9 activity suppresses many genes for mitochondrial proteins including master regulators of 
mitochondrial function PGC-1 and nuclear respiratory factor-1163. In culture, cyclin T1/CDK9 
suppresses PGC-1, decreases mitochondrial membrane potential, and sensitizes cardiomyocytes to 
apoptosis, effects rescued by exogenous PGC-1. Cyclin T1/Cdk9 inhibits PGC-1 promoter activity 
and preinitiation complex assembly. Thus, hypertrophy-induced-activation of CDK9 may contribute 
towards defective mitochondrial function via diminished PGC-1 transcription. Since PGC-1 and 
miR-378 are cotranscribed, this mechanism could in part also explain the downregulation of 
miR-378 during hypertrophy.
5.9 Multilevel regulation of signaling pathways
One of the most intriguing aspects of this study  is the multilevel regulation of the ERK/MAPK 
signaling cascade. MiR-378 targets the ERK/MAPK cascade by directly interfering with IGF1R, 
GRB2, KSR1 and MAPK1. MicroRNAs can be described as fine tuners that aid in the complexity 
of an organism164. Often they  have been described to cause changes by effectively rewiring cell 
specific networks at  all levels of organismal hierarchy, from specific pathways to global regulators. 
Due to speed, reversibility and compartmentalization of microRNA mediated mechanisms, they  are 
ideally  suited to affect rapid, adaptive changes in gene expression to maintain homeostasis or to 
respond to specific signals165. To achieve such effects, microRNAs might be required to rapidly 
repress pathways by  targeting them on multiple levels. In this study we have described the targeting 
of a major signal transduction node on four different levels by  miR-378 affecting the cellular 
response to stress. This is one of the first instances where a much speculated idea has been 
experimentally validated. The ERK/MAPK signaling node is an important effector of a multitude of 
cellular processes. The existence of conserved miR-378 targets within this cascade underscores its 
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evolutionary  importance. MicroRNA binding sites are comparatively less prone to evolutionary 
changes owing to their small sizes compared to other regulatory sites like promoters165. Since 
microRNAs are mostly considered to fine tune cellular processes, for a major phenotypic effect, it 
can be speculated that several microRNAs would need to act together to exert a combinatorial effect 
or one microRNA might  need to regulate multiple targets within a central pathway. There are few 
other studies that offer experimental proof for this hypothesis. The miR-17-92 cluster (a cluster of 6 
miRs) was found to be a potent inhibitor of TGFβ signaling cascade166. They  used SILAC and 
quantitative mass spectrometry techniques to show the cooperation between individual miR-17-92 
miRs in different cellular processes involved in cancer like proliferation and cell adhesion. The 
miR-17-92 cluster was found to be relevant both upstream and downstream of pSMAD2 triggering 
the inhibition of multiple key effectors in the TGFβ-signaling cascade as well as through direct 
inhibition of TGFβ-responsive genes. Another study  with miR-24 showed the regulation of 7 cell 
cycle regulatory genes forming a direct interaction network with genes enhancing cell cycle 
progression167. This regulation is rather atypical because miR-24 regulates the 7 targets namely, 
E2F2, MYC, AURKB, CCNA2, CDC2, CDK4, and FEN1 by recognizing seedless sequences. Our 
current study describes a direct interaction with the 3’ UTR of multiple genes within an important 
signaling node resulting in a strong phenotype linking a microRNA and a specific signaling cascade 
to complex phenomena like hypertrophy and heart failure.
5.10 Therapeutic relevance of AAV based gene therapy
Cardiovascular gene therapies have provided newer and better opportunities to overcome the 
increasing morbidity and mortality rates due to heart failure. In vivo gene therapy using AAVs is 
now a major area of research with successful translation to the clinic. In line with this, our current 
study shows that targeted delivery of miR-378 to the heart could be an effective therapeutic strategy 
to combat myocardial disease. One important aspect of AAV therapy is the issue of toxicity  due to 
overexpression of a gene. However, in our current study, we have only attempted to rescue the 
disease-induced downregulation of miR-378 by bringing it back to physiological levels. It can be 
speculated that by compensating for the loss of a regulatory molecule in a diseased animal, we 
merely attempt to right the balance by reexerting the control normally exerted by the microRNA 
under basal steady  state. An issue of concern regarding AAV-based gene therapy  is the robust 
systemic transduction to off target tissues like the liver. Titration of AAV9 levels have shown 
efficient transduction to heart while minimizing transduction to other tissues like liver and muscle95. 
These strategies that have been proven in mice need to be successfully translated to preclinical large 
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animal models to better understand the limitations and overcome them. Another limitation of using 
AAV for gene therapy  is their limited packaging capacity. However, since miRs relatively are 
smaller than other genes, it  makes them particularly well suited for AAV-based gene therapy. 
Limiting the expression of the miR to a specific cell type within the heart is another major 
challenge. AAV9 has been shown to be myocyte specific in the heart168. In our current study we 
have used AAV9 with a CMV promoter to rescue miR-378 in myocytes. Further studies are required 
to achieve an even higher specificity perhaps through a myocyte specific promoter. 
5.11 Conclusion
MicroRNA-378 is encoded within the intron of the gene Ppargc1b. MiR-378 was identified through 
an automated screening strategy specially  designed to identify miRs regulating hypertrophy  in 
myocytes. MiR-378 was found to be enriched within cardiomyocytes and downregulated in the 
heart. We found that  miR-378 negatively regulated cardiac hypertrophy by inhibiting IGF1R, 
GRB2, KSR1 and MAPK1. Compensation of miR-378 downregulation in a pressure overload 
mouse model using AAV9-based gene transfer protected the heart against hypertrophy and 
dysfunction. Together we propose the hypothesis (Fig 21) that miR-378 negatively regulates cardiac 
hypertrophy  by targeting the ERK/MAPK cascade at four different levels leading to significantly 
improved cardiac function upon pressure overload.
Fig 21. Scheme depicting the control of the MAPK signaling pathway through miR-378.
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6 SUMMARY 
MicroRNAs are endogenous ≈22 nt long non coding RNA molecules that modulate gene expression 
at the post transcriptional level by targeting mRNAs for cleavage or translational repression. 
MicroRNA-mRNA interaction involves a contiguous and perfect pairing within complementary 
sites usually  in the 3’ UTR of the target mRNA. Heart failure is associated with myocyte 
hypertrophy  and death, due to compensatory  pathological remodeling and minimal functional repair 
along with microRNA deregulation. 
In this study, we identified candidate microRNAs based on their expression strength in 
cardiomyocytes and by their ability to regulate hypertrophy. Expression profiling from early  and 
late stages of heart  failure showed several deregulated microRNAs. Of these microRNAs, miR-378 
emerged as a potentially interesting microRNA that was highly expressed in the mouse heart and 
downregulated in the failing heart. Antihypertrophic activity  of miR-378 was first observed by 
screening a synthetic miR library  for morphologic effects on cardiomyocytes, and validated in vitro 
proving the tight control of hypertrophy by this miR. We combined bioinformatic target prediction 
analysis and microarray analysis to identify  the targets of miR-378. These analyses suggested that 
factors of the MAP kinase pathway were enriched among miR-378 targets, namely MAPK1 itself 
(also termed ERK2), the insulin-like growth factor receptor 1 (IGF1R), growth factor receptor-
bound protein 2 (GRB2) and kinase suppressor of ras 1 (KSR1). Regulation of these targets by 
miR-378 was then confirmed by  mRNA and protein expression analysis. The use of luciferase 
reporter constructs with natural or mutated miR-378 binding sites further validated these four 
proteins as direct targets of miR-378. RNA interference with MAPK1 and the other three targets 
prevented the prohypertrophic effect of antimiR-378, suggesting that they  functional relate to 
miR-378. In vivo restoration of disease induced loss of miR-378 in a pressure overload mouse 
model of hypertrophy using adeno associated virus resulted in partial attenuation cardiac 
hypertrophy  and significant improvement in cardiac function along with reduced expression of the 
four targets in heart. 
We conclude from these findings that miR-378 is an antihypertrophic microRNA in 
cardiomyocytes, and the main mechanism underlying this effect is the suppression of the MAP 
kinase-signaling pathway on four distinct levels. Restoration of disease-associated loss of miR-378 
through cardiomyocyte-targeted AAV-miR-378 may prove as an effective therapeutic strategy in 
myocardial disease.
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Zusammenfassung
MicroRNAs sind ca. 22 Nukleotide lange endogene, nicht-kodierende RNA-Moleküle, die die 
Expression von Genen posttranskriptionell regulieren, indem sie den Abbau der Ziel-mRNA 
herbeiführen oder deren Translation hemmen. Die Interaktion von microRNA und mRNA erfolgt 
durch perfekt komplementäre Bindung in der 3’-untranslatierten Region der Ziel-mRNA. Eine 
Deregulation der Expression verschiedener microRNAs lässt sich bei Herzinsuffizienz beobachten. 
Im insuffizienten Herzen laufen kompensatorische pathologische Remodellingprozesse ab und es 
kommt unter anderem zu Hypertrophie und Apoptose von Kardiomyozyten.
Im Rahmen dieser Arbeit haben wir Kandidaten-microRNAs nach folgenden Kriterien identifiziert: 
1 ) Express ionss tä rke in Kard iomyozyten , 2 ) Fäh igke i t  zur Regula t ion von 
Kardiomyozytenhypertrophie im Screening einer synthetischen microRNA-Bibliothek auf 
Kardiomyozytengröße und 3) Regulation ihrer Expression in frühem und späten Stadium eines 
murinen Herzinsuffizienzmodells. Aus den resultierenden Kandidaten-microRNAs wurde im 
folgenden miR-378 näher untersucht. MiR-378 war im gesunden Mausherz stark exprimiert. Die 
Expression nahm bei Herzinsuffizienz ab. Weiterhin hatte die Überexpression von miR-378 in 
neonatalen Kardiomyozyten einen antihypertrophen Effekt. Im Gegenzug führte die Expression von 
antimiR-378 zu einer verstärkten Hypertrophie. Zur Target-Suche wurden zum einen 
bioinformatische Vorhersage-Datenbanken verwendet und zum anderen ein Microarray 
durchgeführt. Diese Analysen zeigten eine Anreicherung von Faktoren des MAP-Kinase-
Signalweges: Mitogen-aktivierte Proteinkinase 1 (MAPK1, auch als ERK2 bezeichnet), Insulin-
ähnlicher Wachstumsfaktorrezeptor 1 (IGF1R), Wachstumsfaktorbindeprotein 2 (GRB2) und 
Kinasesuppressor von Ras 1 (KSR1). Die Regulation dieser Targets durch miR-378 wurde durch 
Bestimmung der mRNA- und Proteinexpression nach Überexpression bzw. Inhibition von miR-378 
bestätigt. Durch Luziferaseassays mit Reporterkonstrukten, die jeweils die exakten oder mutierte 
Bindungsstellen der vier Targets enthielten, konnte gezeigt werden, dass die mRNAs der vier 
Faktoren direkte Targets von miR-378 darstellen. Durch siRNA-mediierte Herabregulation der 
Zielproteine konnte der prohypertrophe Effekt von antimiR-378 inhibiert werden. Daraus lässt sich 
schließen, dass der Hypertrophie-Phänotyp direkt auf miR-378 zurückzuführen ist. Schließlich 
wurde der Effekt von miR-378 im murinen Herzinsuffizienzmodell (Konstriktion der Aorta, TAC) 
untersucht. TAC führte zu einer Abnahme der Expression von miR-378 im Herzen. Durch Adeno-
assoziierten Virus (AAV) vermittelte exogene Expression von miR-378 wurde das Expressionslevel 
des gesunden Herzens im TAC-Modell wiederhergestellt  und die Expression der vier Targets 
herabgesetzt. Dies resultierte in weniger ausgeprägten Kardiomyozytenhypertrophie sowie in einer 
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signifikanten Verbesserung der Herzfunktion. 
Aus diesen Daten schließen wir, dass miR-378 einen antihypertrophen Effekt auf Kardiomyozyten 
hat, der wesentlich durch die Suppression des MAP-Kinase-Signalweges an vier Angriffspunkten 
vermittelt wird. Die Wiederherstellung des “gesunden” Expressionsniveaus von miR-378 im 
kranken Herzen durch Kardiomyozyten-spezifische Expression mit AAV-miR-378 könnte eine 
Therapieoption bei Herzerkrankungen sein.
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8 ADDENDUM
8.1 Abbreviations
AAV
AGO
ANP
BCA
BSA
CDC42
CDK
DCM
DGCR8
DYRK1A
EF
ERK
ERR
FCS
FS
FUS1
GDP
GPCR
GRB2
GTP
IGF1
IGF1R
ITR
IVS
JNK
KSR1
LVID
LVPW
MAPK
MCS
MEF2
MiRNA/miR
MIRNP
NELFA
NFAT
NRCM
PACT
PBS
PE
Adeno-associated virus
Argonaute
Atrial natriuretic peptide
Bicinchoninic acid
Bovine serum albumin
Cell division control protein 42 homolog
Cyclin-dependent kinase
Dilated cardiomyopathy
DiGeorge critical region 8
Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1a 
Ejection fraction
Extracellular signal-regulated kinases
Estrogen-related receptors 
Fetal calf serum
Fractional shortening
Fused in sarcoma 1
Guanosine diphosphate,
G protein coupled receptor
Growth factor receptor-bound protein 2
Guanosine-5'-triphosphate
Insulin-like growth factor 1
Insulin-like growth factor 1 receptor
Inverted terminal repeats 
Intraventricular septal thickness
c-Jun N-terminal kinase
Kinase suppressor  Ras 1
Left ventricular internal diameter 
Left ventricular posterior wall thickness
Mitogen-activated protein kinase
Multiple cloning site
Myocyte enhancer factor-2 
MicroRNA
Micro-ribonucleoprotein
Negative elongation factor A 
Nuclear factor of activated T-cells
Neo natal rat cardiomyocyte
Protein activator of PKR
Phosphate buffered saline
Phenylephrine
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PGC1
PI3K
PIWI
QPCR
RAS
RASA1
RASSF1
RHEB
RHOA
RISC
SDS
SHRNA
SIRNA
SRF
SUFU
TAC
TAE
TGFβ
TRBP
TUNEL
UTR
WGA
XPO5
βMHC
Peroxisome proliferator-activated receptor gamma coactivator 1
Phosphatidylinositol-4,5-bisphosphate 3-kinase 
P-element induced wimpy testis
Quantitative real time PCR
Rat sarcoma
Ras GTPase activating protein
Ras-association domain family-1
Ras homolog enriched in brain
Ras Homolog Family Member A
RNA-induced silencing complex
Sodium dodecyl sulfate
short hairpin RNA
small interfering RNA
Serum response factor
Suppressor of fused homolog 
Transverse aortic constriction
Tris-acetate-EDTA
Transforming growth factor beta
Tar RNA binding protein)
Terminal deoxynucleotidyl transferase dUTP nick end labeling 
Untranslated region
Wheat germ agglutinin
Exportin-5
Myosin heavy chain beta
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